Prophetic Patents by Freilich, Janet
Fordham Law School 
FLASH: The Fordham Law Archive of Scholarship and History 
Faculty Scholarship 
2019 
Prophetic Patents 
Janet Freilich 
Fordham University School of Law, jfreilich1@fordham.edu 
Follow this and additional works at: https://ir.lawnet.fordham.edu/faculty_scholarship 
 Part of the Law Commons 
Recommended Citation 
Janet Freilich, Prophetic Patents UC Davis L. Rev. (2019) 
Available at: https://ir.lawnet.fordham.edu/faculty_scholarship/1006 
This Article is brought to you for free and open access by FLASH: The Fordham Law Archive of Scholarship and 
History. It has been accepted for inclusion in Faculty Scholarship by an authorized administrator of FLASH: The 
Fordham Law Archive of Scholarship and History. For more information, please contact 
tmelnick@law.fordham.edu. 
                               
PROPHETIC PATENTS 
 
Janet Freilich* 
 
In most contexts, making up data is forbidden - considered fraudulent, even 
immoral. Not so in patents.  Patents often contain experimental data, and it is 
perfectly acceptable for these experiments to be entirely fictional. These so-called 
“prophetic examples” are not only explicitly permitted by both the Patent Office 
and federal courts, but are considered equivalent to factual data in patent doctrine. 
Though prophetic examples are thought to be common, there are no in-depth 
studies of the practice, nor any explanation for why fictional data are allowed in 
patents.   
  
Here, I provide the first historical, theoretical, and empirical analysis of 
prophetic examples. I collect and analyze a novel dataset of over 2 million U.S. 
patents and applications from the biology and chemistry industries. I find that at 
least 17% of experiments in this population are fictional. Through both empirical 
and theoretical analyses, I weigh the potential costs and benefits of prophetic 
examples and find that the costs prevail. Prophetic examples could be beneficial if 
they help patentees; but I find little evidence that they do so, even in the specific 
situations in which they should be the most useful. Instead, prophetic examples 
likely hinder innovation because they prevent others from conducting their own 
experiments – even after the patent has expired and even if the prophetic example 
is incorrect. Prophetic examples also hopelessly confuse scientists – a shocking 
99% of scientific articles incorrectly cite prophetic examples as if they contained 
factual information – which means that made-up results from patents contaminate 
the scientific literature. 
 
Given these harms, I argue for a shift from prophesies to more clearly 
delimited hypotheses – roadmaps for future research, but nothing more – 
preserving what value there is in speculation while mitigating the clear harms of 
the practice. Beyond these concrete policy recommendations, my findings also 
have rich implications for theoretical debates about the physicality of invention, 
when and to whom patents should be granted, how patents transmit information, 
and, ultimately, how best to incentivize innovation.   
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INTRODUCTION 
 
In May of 2005, a team of scientists made headlines after the 
prestigious journal Science published a report that they had cloned human 
embryos.1 Only a few months later, the team was making headlines for a 
different reason: the data in the paper had been faked; Science retracted the 
paper and the team’s leader, Dr. Hwang Woo-Suk, was fired and spent two 
years in prison for violating bioethics rules.2 Almost ten years after the 
retraction, Dr. Hwang received a U.S. patent on his discredited technique.3 
Other scientists were “shocked” by the news that Dr. Hwang obtained a patent 
for falsified data.4 The New York Times quoted Dr. Jeanne Loring, a stem cell 
scientist at Scripps Research Institute, saying that her first reaction was, “You 
can’t patent something that doesn’t exist.”5  
 
Dr. Loring’s reaction is common, sensible, and intuitive—but wrong. 
The Patent and Trademark Office (PTO) and the courts explicitly permit made 
up experiments and fictional data in patents.6 Far from fraudulent, fictional 
data is instead treated as equivalent to factual data.7 To illustrate, the fictional 
experiment below was published in a recently granted patent: 
 
A 67-year old male has pancreatic cancer...He is provided with A. 
paucinervis pomel extract [the patented invention] for three years. 
The patient is examined later and…[h]is tumor is reduced in mass...8 
 
The supposed ability of the patented compound to cure cancer borders on 
miraculous – yet it is also highly improbable, as real experiments have found 
the compound to be extremely toxic.9 
 
There is little scholarship on these fictional experiments – commonly 
called “prophetic examples.” The articles that have mentioned prophetic 
examples do so only in passing, with no more than a few sentences dedicated 
                                                 
1 Gina Kolata, Koreans Report Ease in Cloning for Stem Cells, N.Y. TIMES (May 20, 
2005). 
2 Andrew Pollack, Disgraced Scientist Granted U.S. Patent for Work Found to be 
Fraudulent,  N.Y. TIMES  (Feb. 14, 2014). 
3 Id. The patent in question is U.S. Patent No. 8,647,872 (issued Feb. 11, 2014).  
4 Pollack, supra note 2 (“‘Shocked, that’s all I can say,’ said Shoukhrat Mitalipov, a 
professor at Oregon Health and Science University who appears to have actually accomplished 
what Dr. Hwang claims to have done. ‘I thought somebody was kidding...’”). 
5 Id. 
6 U.S. PATENT & TRADEMARK OFFICE, MANUAL OF PATENT EXAMINING PROCEDURE 
[hereinafter “MPEP”] § 608 (9th ed. 2015); Atlas Powder Co. v. EI Du Pont De Nemours, 750 
F.2d 1569, 1577 (Fed. Cir. 1984). 
7 DONALD CHISUM, CHISUM ON PATENTS § 2212 (2015). 
8 U.S. Patent No. 8,003,137, Example 15 (issued Aug. 23, 2011).  
9 Frederic D. Debelle, Jean-Louis Vanherweghem, & Joelle L. Nortier, Aristolochic Acid 
Nephropathy: A Worldwide Problem, 74 KIDNEY INT’L 158, 158 (2008). These experiments 
were conducted before the patent issued, so they did not infringe on the patent. 
 
to the issue.10 These articles are almost uniformly critical of prophetic 
examples – hinting at potential problems surrounding the practice.11 Despite 
the lack of scholarly attention, prophetic examples are common.12 It is possible 
that the PTO has been granting hundreds of thousands of patents based on 
fake, implausible, and unreplicable experiments – and we know nothing about 
it.  
 
In this Article, I set out to understand the history, prevalence, and impact of 
prophetic examples. I collected a unique data set consisting of all prophetic and 
non-prophetic examples from US patents and applications published between 
1976 and 2017.13 To identify prophetic examples, I exploited a PTO rule that 
requires prophetic examples to be written in the present or future tense, while 
non-prophetic examples are written in the past tense.14 I focused on chemistry 
and biology patents, as those are the only industries that commonly include 
experimental data (real or otherwise) in patents.15 I analyzed 2,214,551 patents 
                                                 
10 Andrew Baluch, Relating the Two Experimental Uses in Patent Law, 87 B.U. L. REV. 
213, 241 (2007) (mentioning that prophetic examples may lead to “[a]n inventor’s overreach”); 
Robin Feldman, Plain Language Patents, 17 TEX. INTELL. PROP. L.J. 289, 292 (2009) 
(criticizing the code for distinguishing prophetic examples); Timothy Holbrook, Possession in 
Patent Law, 59 SMU L. REV. 123, 158 (2006) (explaining that prophetic examples may chill 
downstream research); Timothy Holbrook, Equivalency and Patent Law’s Possession 
Paradox, 23 HARV. J.L. & TECH. 1, 9 (2009) (suggesting that prophetic examples may increase 
incentives to innovate); Dmitry Karshtedt, Limits on Hard-to-Reproduce Inventions, 3 
HASTINGS SCI. & TECH. L.J. 109, 114 (2011) (writing about the difference between scientific 
norms for reporting experiments and prophetic examples, but noting that they may disclose 
valuable inventions that would not otherwise come to light); Mark Lemley, Ready for 
Patenting, 96 B.U. L. REV. 1171, 1178 (2016) (suggesting that prophetic examples 
“disadvantage inventors who actually build and test their inventions before filing a patent 
application.”); Lisa Larrimore Ouellette, Pierson, Peer Review, and Patent Law, 69 VAND. L. 
REV. 1825, 1827 (worrying that prophetic examples result in the “award of patents earlier than 
is socially optimal”); Lisa Larrimore Ouellette, Who Reads Patents?, 35 NATURE 
BIOTECHNOLOGY 421, 422 (2017) (noting that scientists who read patents may not be aware 
that prophetic examples are not real experiments); Kristen Osenga, Cooperative Patent 
Prosecution, 85 ST. JOHN’S L. REV. 115, 158 (2011) (discussing the difference between 
prophetic examples and scientific writing); Sean Seymore, Patenting Around Failure, 166 U. 
PENN. L. REV. (forthcoming 2018); Sean Seymore, The Teaching Function of Patents, 85 
NOTRE DAME L. REV. 621, 632 (2010); Sean Seymore Heightened Enablement in the 
Unpredictable Arts, 56 UCLA L. REV. 127, 144 (2009) (arguing in each article that the 
experiments described in prophetic examples are probably not correct.). 
11 Id. 
12 Smith Kline & French Laboratories v. Teva Pharmaceuticals USA, Inc., 2006 WL 
6331923 (D.Del. 2012), Expert Report of Egon E. Berg (Sept. 22, 2006) (“Based on my 
experience as a patent attorney and patent examiner…prophetic examples are also common in 
patents”). 
13 Part III.A, infra.  
14 MPEP § 608. 
15 Part III.B, infra. Note that the problem of fictional experiments is certainly present in 
other industries. See HAROLD FULLMER, PATENT PROSECUTION 277 (2017). Further, the theory 
and policy discussed herein also applies across industries.  The empirical study focuses on 
chemistry and biology because the methodology is best suited to those industries.  However, 
the implications of this Article are not so limited.  
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and applications in those industries, a population that contains 12,300,156 
examples.16  
 
I confirm that prophetic examples are indeed common: in chemistry and 
biology patents issued between 1976 and 2017, at least 17% of examples are 
prophetic, and, of patents with examples, at least 24% contain some prophetic 
experiments.17 This means that prophetic examples are widespread enough to 
seriously impact patent law – and that we need to know more about them. 
 
At first glance, the practice of allowing prophetic examples in patents 
seems baffling – why would the PTO allow fictional data? The PTO has never 
explicitly stated its reasons, but it is possible to construct a strong theoretical 
case for prophetic examples and then test it empirically, which I do here.  
 
The theoretical case for prophetic examples rests on benefit to patentees. 
The Patent Act requires inventors to describe how to make and use their 
invention.18 Inventors often do this by writing experimental protocols and 
results in the patent.19 For example, a patent on a diabetes medication might 
include an experiment showing how to synthesize the molecule and another 
showing that the molecule can be given to humans to reduce the need for 
insulin injections.20 The broader the patent, the more experiments are 
required.21 A patent covering one molecule might only need to include one 
synthesis protocol, whereas a patent covering a family of one hundred 
molecules might need to include many more experiments.22 It is always faster 
and cheaper to make up data than to conduct real experiments, so if the 
experiments disclosed in the patent can be fictional, inventors will be able to 
file broader patents more easily.23 This should be particularly useful for small 
companies, who have small budgets and cannot afford extensive real 
experimentation.24 For companies of all sizes, broader patents provide a greater 
reward to the inventor, which might incentivize more innovation.25  
 
I test this hypothesis empirically and find there is surprisingly little 
evidence that prophetic examples actually help patentees. Patents with more 
                                                 
16 Because some applications become granted patents, not all of these prophetic examples 
are unique. See Table 1, infra, for more information. 
17 Table 1 and accompanying text, infra. 
18 35 U.S.C. § 112. 
19 In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988). 
20 U.S. Patent No. 6,916,848 col. 13, ll. 23-45, col. 67, ll. 30-67 (issued July 12, 2005). 
21 See, e.g., ALZA Corp. v. Andrx Pharmaceuticals, LLC, 603 F.3d 935, 942 (Fed. Cir. 
2010). 
22 See, HAROLD C. WEGNER, FIRST TO FILE PATENT DRAFTING § 8:5 (2016). 
23 Part II.A.1, infra. 
24 Irwin Aisenberg, The Patent and Present of Working Examples, 23 IDEA 25, 30 (1982). 
25 E.g., Bonito Boats, Inc. v. Thunder Craft Boats, Inc., 489 US 141, 146 (1989) 
(explaining that the purpose of patents is to incentivize innovation, and that this is done, in 
part, by giving inventors the exclusive right to make and use their invention). 
 
prophetic examples are narrower than patents with fewer prophetic examples – 
despite the prediction that prophetic examples help patentees get broader 
patents.26 Second, there is no evidence that patents with more prophetic 
examples are filed earlier than those with fewer prophetic examples – again, 
contrary to prediction.27 Finally, although small companies should benefit 
disproportionately from the ability to use prophetic examples, they do not. I 
find that small companies are significantly less likely to use prophetic 
examples as compared to their larger counterparts.28 In sum, the case for 
prophetic examples does not fit with the empirical evidence. 
 
Evidence for the benefits of prophetic examples is weak; but evidence for 
their harms is much stronger. Patents with prophetic examples are frequently 
abandoned, which suggests that the inventor is not commercializing their 
invention.29 The problem is that, because of the patent, neither is anybody else. 
While in force, the patent prevents others from working in that area.30 Even 
after the patent has been abandoned and no longer has legal force, a chilling 
effect remains. Because patents are granted only if an invention has not been 
previously disclosed, it is difficult for any subsequent inventor to get a patent 
in an area previously described by a prophetic example.31 This is true even if 
the prophetic example is incorrect and the subsequent inventor was the first to 
actually make a functioning prototype.32 Essentially, instead of incentivizing 
innovation, prophetic examples may create an innovation dead zone. 
 
Prophetic examples also lead to a second type of harm: they mislead 
scientists. In their patent, inventors must disclose a detailed description of their 
invention that can be used by other scientists to build further upon the 
technology.33 This disclosure function of patents has long been recognized as a 
crucial element of innovation – allowing downstream innovators to see further 
by metaphorically standing on the shoulders of giants.34 However, the 
disclosure function breaks down if scientists are misled by the disclosed 
information. 
 
I analyzed how prophetic examples were cited in scientific publications 
                                                 
26 Part III.D.1.b, infra. 
27 Part III.D.1.c, infra. 
28 Part III.D.1.d, infra. 
29 Part III.D.1.a, infra. 
30 35 U.S.C. § 271. 
31 35 U.S.C. § 102-103. 
32 To anticipate a subsequent patent, the prior prophetic example must be enabled. MPEP 
§ 2121.01. However, this is not a requirement for obviousness. Id. Further, prophetic examples 
in granted patents are presumed to be enabled, so proving otherwise involves a legal battle and 
is sufficient to dissuade others from working in an area. Id. 
33 35 U.S.C. § 112. 
34 E.g., Graham v. John Deere, 383 US 1, 6 (1966) (“…things which add to the sum of 
useful knowledge are inherent requisites in a patent system which by constitutional command 
must ‘promote the Progress of…useful Arts.’”). 
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and found that ninety-nine percent of citations to prophetic examples 
incorrectly cited the example as if it represented work that had actually been 
done.35 This would not necessarily be a problem if the prophetic examples 
were good predictions, but, as I demonstrate in this Article, many prophetic 
examples are probably wrong.36 False information is infiltrating the scientific 
community by way of prophetic examples.  
 
My empirical findings have implications for several core debates in patent 
theory, including the disclosure function of patents, theories about constructive 
reduction to practice, and the optimal timing of patent filing. For disclosure, 
the misinformation spread by prophetic examples adds strength to widespread 
accusations that disclosure functions poorly and furthers a line of the literature 
emphasizing the gap between scientific writing and “patentese.”37 For 
constructive reduction to practice – a doctrine that allows inventors to obtain a 
patent without having physically created the invention – scholars argue that it 
disincentivizes physical reduction to practice.38 However, my evidence 
suggests that, surprisingly, there may be more advantages to physical invention 
than previously realized.39 For the optimal timing of patent filing, I show that 
while proponents of early filing might be expected to favor mechanisms that 
contribute to earlier filing, some such mechanisms – such as prophetic 
examples – do not fit with the traditional justifications for early filing.40  
 
All of this strongly argues for reform.  Banning fictional experiments in 
patents is an attractive solution, given the findings herein, but likely too drastic 
an institutional change (for now).  Instead, I argue that we should not think 
about fictional experiments as prophecies – a name that carries of ring of 
accuracy and infallibility – but rather as hypotheses – testable predictions that 
may or may not turn out to be correct.41 The shift from prophecies to 
hypotheses has several practical implications. First, it would reverse the 
current legal presumption that prophetic examples are enabled (i.e. that they 
work as written), since, as I show empirically, there is simply no reason to 
assume accuracy. Second, we should give inventors a grace period after filing 
to test their hypotheses and update prophetic examples with real results. 
Finally, we should require prophetic examples to be clearly labeled and to 
include some explanation about why the inventor expects the experiment to 
work. These changes all reflect that the predicted results are possibilities, not 
inevitabilities, and the shift can preserve what value such speculation has, 
while mitigating the clear harms that now prevail. 
 
                                                 
35 Part III.D.2.b, infra. 
36 Part IV.B.1, infra 
37 Part III.D.2.b, infra 
38 Part IV.B.2, infra. 
39 Part IV.A.2.c, infra 
40 Part IV.A.2.b, infra. 
41 Part IV.C, infra. 
 
The Article proceeds as follows. Part I provides background on prophetic 
examples, introducing the concept and related doctrine, as well as sketching 
their historical development. Part II makes the case for prophetic examples, 
and discusses costs and benefits.  Part III, the heart of the Article, provides a 
novel empirical study of prophetic examples, explaining the study’s design and 
methodology, and then providing data.  Part IV then explains the study’s 
results, examines the theoretical implications of the study for patent theory, 
and concludes with a proposal for policy reform. 
 
I. PROPHETIC EXAMPLES 
 
Prophetic examples are experiments that report protocols that were not 
actually conducted and describe results that are made up, or prophesized.42 
There is little literature on prophetic examples,43 so this Section provides an in-
depth exploration of the practice of prophesy in patents. Section I(a) is an 
introduction to prophetic examples and summarizes current doctrine. Section 
I(b) traces the history of prophetic examples, exploring why they were 
originally used and explanations for their existence.  
 
A.  Introduction to Prophetic Examples 
 
The Patent Act requires that every patent contain a written description of 
the invention as well as information on how to make and use it.44 These 
disclosure requirements ensure that the inventors obtain a monopoly 
commensurate with what they have actually invented.45 Disclosure is also 
intended to promote innovation by ensuring that scientists and can read and use 
the information in the patent and thereby build further on the technology.46 The 
requirements are a quid-pro-quo to guarantee that the public receives the 
benefit of knowledge in exchange for granting an exclusive patent.47 In the 
absence of patents, inventions that could be kept secret might never be taught 
to the public.48  
  
The disclosure statute has two components: enablement and written 
                                                 
42 MPEP § 608. 
43 Note 10, supra. 
44 35 U.S.C. § 112. 
45 Dan L. Burk, Patent Silences, 69 VAND. L. REV. 1603, 1606 (2016). 
46 E.g., Graham v. John Deere, 383 US 1, 6 (1966). 
47 Lisa Larrimore Ouellette, Pierson, Peer Review, and Patent Law, 69 VAND. L. REV. 
1825, 1827 (2016). 
48 Sean O’Connor & Ted Sichelman, Patent as Promoters of Competition: The Guild 
Origin of Patent Law in the Venetian Republic, 49 SAN DIEGO L. REV. 1267, 1272 (2012). In 
practice, some aspects of patented inventions are still kept secret. See W. Nicholson Price II, 
Making do in Making Drugs: Innovation Policy and Pharmaceutical Manufacturing, 55 B.C. 
L. REV. 491 (2014); W. Nicholson Price II & Arti K. Rai, Are Trade Secrets Delaying 
Biosimilars, 10 SCIENCE 188, 188 (2015). 
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description.49 The enablement doctrine requires that the patent include 
sufficient detail to ensure that a person skilled in the field of the invention 
could make and use the invention.50 The written description doctrine requires 
that the patent include sufficient detail to prove that the inventor was in 
possession of the invention when she filed the application.51 Possession does 
not refer only to physical possession of the invention.52 The requirement can be 
met if the inventor clearly describes the invention in the patent.53 
 
These requirements can be satisfied in many ways, but it is common to 
provide examples of how the invention is made or used.54 Examples often 
describe experiments, and may provide instruction on how to make a 
composition or the effects of using said composition.55 They are sometimes 
analogized to the “Materials and Methods” and “Results” sections of scientific 
articles.56 While examples are not required,57 they are frequently included in 
patents58 and the absence thereof is frowned upon by courts.59  
 
There are two types of examples: (1) “working examples,” which report 
experiments actually conducted; and (2) “prophetic examples,” which report 
experiments that were not actually conducted and describe content that is made 
up, or prophesized.60 The Patent Office defines prophetic examples as “an 
embodiment of the invention based on predicted results rather than work 
actually conducted or results actually achieved.”61 I give excerpts from 
prophetic and non-prophetic examples below, to give the reader their flavor. 
The following two examples come from U.S. Patent No. 6,869,610 which 
claims methods of treating pain by administration of Botox.62 The patent 
contains one non-prophetic example, describing experiments conducted on 
rats, and several prophetic examples, describing the predicted effects of 
administering Botox to humans.  
                                                 
49 Ariad Pharm., Inc. v. Eli Lilly and Co., 598 F. 3d 1336, 1341 (Fed. Cir. 2010). 
50 35 U.S.C. § 112; In re Wands, 858 F.2d 731, 736 (Fed. Cir. 1988). 
51 35 U.SC. § 112; Ariad, 598 F. 3d at 1341. 
52 Falko-Gunter Falkner v. Inglis, 448 F.3d 1357, 1366 (Fed. Cir. 2006). 
53 MPEP § 2163.02 (“An applicant shows possession of the claimed invention by 
describing the claimed invention with all of its limitations using such descriptive means as 
words, structures, figures, diagrams, and formulas that fully set forth the claimed invention.”). 
54 MPEP § 2164.02. 
55 E.g., Application of John A. Stephens, 529 F.2d 1343, 1345 (CCPA 1976). 
56 PRACTICING LAW INSTITUTE, HOW TO WRITE A PATENT APPLICATION, 17-26 (2016). 
57 In re Wright, 999 F.2d 1557, 1561 (Fed. Cir. 1993). 
58 In re Strahilevitz, 668 F.2d 1229, 1232 (CCPA 1982). 
59 See, e.g., Wyeth v. Abbott Laboratories, 2012 WL 175023, *11 (D.N.J. 2012), aff’d on 
other grounds, 720 F.3d 1380, 1384 (Fed. Cir. 2013); Boston Scientific Corp. v. Johnson & 
Johnson Inc., 2010 WL 183752, *13 (D.Del. 2010). 
60  MPEP § 608.01(p). 
61 MPEP § 2164.02. See also CHISUM, supra note 7, at § 10.05 (calling prophetic 
examples “specific illustrations of the invention that have not, in fact, been carried out.”); Paul 
R. Gugliuzza, Early Filing and Functional Claiming, 96 B.U.L. REV. 1223, 1226 (2016) 
(calling prophetic examples “basically, educated speculations...”). 
62 U.S. Patent No. 6,869,610 (issued Mar. 22, 2005). 
 
 
Non-Prophetic Prophetic 
Two experiments were carried out…[using] 
rats…there were 4 treatment (dose) groups: 
control (saline injected) rats…and 7 U 
BOTOX®/KG rats...Limb lifting/licking by 
the subject animals was recorded…at both 
5 days and 12 days after injection, there 
was a significant dose dependent pain 
alleviation in the BOTOX® treated 
animals.63 
A 46 year old woman presents with pain localized 
at the deltoid region due to an arthritic condition. 
The muscle is not in spasm, nor does it exhibit a 
hypertonic condition. The patient is treated by a 
bolus injection of…intramuscular botulinum toxin 
type A. Within 1-7 days after neutrotoxin 
administration the patient’s pain is substantially 
alleviated. The duration of significant pain 
alleviation is from about 2 to about 6 months.64 
 
The Patent Office and the federal courts explicitly permit prophetic 
examples.65 Both institutions have also confirmed that prophetic examples can 
be used to satisfy the enablement and written description requirements in the 
same manner as working examples could be so used. To satisfy the enablement 
requirement, applicants must describe the invention sufficiently to enable 
another person in the field to make and use the claimed invention.66 Prophetic 
examples teach strategies for making and using the invention, and thus help 
satisfy the enablement requirement.67 For the written description requirement, 
applicants must disclose the invention in sufficient detail to show that they 
were in possession of the invention when they filed the patent.68 Prophetic 
examples help demonstrate that the patentee knew about the contours of the 
invention, and thus help satisfy the written description requirement.69 Patents 
must also contain a statement of utility to be valid,70 and prophetic examples 
can be used to illustrate the utility of the invention.71  
 
                                                 
63 Id. at Example 1. 
64 Id. at Example 2. 
65 Atlas Powder Co. v. EI du Pont De Nemours, 750 F.2d 1569, 1577 (Fed. Cir. 1984); 
MPEP § 2164.02. 
66 35 U.S.C. § 112.  
67 Alcon Research Ltd. v. Barr Laboratories, 745 F.3d 1180, 1189 (Fed. Cir. 2014); 
Energy Absorption Systems, Inc. v. Roadway Safety Services, Inc., 1997 WL 368379, *5 (Fed. 
Cir. 1997); Boston Scientific Corp. v. Johnson & Johnson Inc., 679 F.Supp.2d 539, 552 
(D.Del. 2010) (“the burden is on one challenging validity to show, by clear and convincing 
evidence, that the prophetic examples together with other parts of the specification are not 
enabling.”); Cephalon, Inc. v. Watson Pharmaceuticals, Inc., 769 F.Supp.2d 729, 750 (D.Del. 
2011). 
68 Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co., 598 F.3d 1336, 1343 (Fed. Cir. 2010). 
69 Ariad, 598 F.3d at 1357 (confirming that prophetic examples “certainly can be sufficient 
to satisfy the written description requirement”); Application of Robbins, 429 F.2d 452, 457 
(CCPA 1970). 
70 35 U.S.C. § 101. 
71 E.g. Rebecca S. Eisenberg & Robert P. Merges, Opinion Letter as to the Patentability of 
Certain Inventions Associated with the Identification of Partial Cdna Sequences, 23 AIPLA 
Q.J. 1, 16 (1995) (explaining that patent examiners are sometimes skeptical of prophetic 
examples illustrating utility). See also, Michael Risch, Reinventing Usefulness, 2010 BYU L. 
Rev. 1195, 1202. 
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Though prophetic examples can serve the same function as working 
examples, inventors cannot pass off prophetic examples as work that has 
actually been done. Prophetic examples must be written in the present tense, 
while working examples are written in the past tense.72 The Federal Circuit 
held that writing prophetic examples in the past tense can be inequitable 
conduct,73 though district courts hearing cases on the question have produced 
mixed results.74 A finding of inequitable conduct, essentially fraud, can render 
the patent unenforceable.75 However, prophetic examples recited in the present 
tense are unquestionably not inequitable conduct, a principle that has needed 
repeating by the Federal Circuit and district courts.76 
 
B.  History of Prophetic Examples 
 
The practice of allowing fictional information in a legal document is 
unusual; it is not intuitive how such a practice might develop or why it might 
be permissible. The Section below traces the development of prophetic 
examples. 
 
1. Early History 
 
Most of the earliest U.S. patents were mechanical or electrical.77 
Mechanical and electrical inventions are relatively “predictable,” meaning that 
a skilled engineer reading a patent disclosing one model of an apparatus could 
predict how variations of the disclosed apparatus would perform.78 This 
disclosure was often a drawing of a machine (as opposed to just text), which 
the skilled engineer could follow to build and use the machine.79 Over time, 
this disclosure came to be considered sufficient evidence of invention – a 
physical model was not needed.80 This doctrine, called “constructive reduction 
                                                 
72 MPEP § 608. 
73 Hoffmann-La Roche, Inc. v. Promega Corp., 323 F.3d 1354, 1364 (Fed. Cir. 2003). See 
also Purdue Pharma. L.P. v. Endo Pharmaceuticals Inc., 438 F.3d 1123, 1134 (Fed. Cir. 2006); 
Novo Nordisk v. Bio-Tech Gen. Corp., 424 F.3d 1354, 1364, 1368 (Fed. Cir. 2005).  
74 Compare Presidio Components Inc. v. American Technical Ceramics Corp., 2010 WL 
1462757, *28 (S.D.Cal. 2010) with Apotex, Inc. v. UCB, Inc., 970 F.Supp.2d 1297, 1319 
(S.D.Fla. 2013). Note that the Federal Circuit clarified the inequitable conduct standard in the 
years between Presidio and Apotex. Therasense, Inc. v. Becton, Dickinson and Co., 649 F.3d 
1276, 1279 (Fed. Cir. 2011). 
75 American Calcar v. American Honda, 768 F.3d 1185, 1186 (Fed. Cir. 2014). 
76 E.g., Energy Absorption Systems, Inc. v. Roadway Safety Services, Inc., 1997 WL 
368379, at *5 (Fed. Cir. 1997); Eli Lilly and Co. v. Actavis Elizabeth LLC, 676 F.Supp.2d 
352, 363 (D.N.J. 2009), rev’d on other grounds 435 Fed.Appx. 917 (Fed. Cir. 2011).  
77 Sean B. Seymore, The Enablement Pendulum Swings Back, 6 NW. J. TECH. & INTELL. 
PROP. 278, 282 (2008). 
78 Id. 
79 Drawings are still used to satisfy patent disclosure requirements. 35 U.S.C. § 113. 
80 35 U.S.C. § 114 empowers the PTO to ask applicants for a model of their invention, but 
“[w]ith the exception of cases involving perpetual motion, a model is not ordinarily required 
by the Office…” MPEP § 608.03.  
 
to practice” allowed inventors to obtain patents on anything they could 
describe in sufficient detail to teach others to make, even if the inventor had 
never physically made the invention.81  
 
In the early twentieth century the field of organic chemistry burgeoned and 
the number of chemistry patents skyrocketed.82 Drawings – a great aid in 
teaching mechanical inventions – were less helpful for chemical patents.83 
Although a drawing of a molecule shows its structure, it is not always clear 
from that structure how to synthesize the molecule or what the molecule’s uses 
might be. To ensure that chemistry patents had adequate disclosure of how to 
make and use the invention, patent drafters turned to “examples” – 
experimental protocols that supported the chemical claim in the same way that 
drawings traditionally had for mechanical patents.84 Though examples were 
not strictly necessary to enable a chemical invention,85 courts often rejected 
chemistry patents that lacked examples86 and patent prosecutors believed that a 
large number of examples would help their case.87 Examples therefore became 
a standard part of chemistry patents. 
 
Unlike the mechanical sciences, chemistry is “essentially an experimental 
science and results are often uncertain, unpredictable and unexpected.”88 In 
unpredictable fields, it is often not possible to predict how minor variations in 
the invention will affect the results.89 The doctrine of constructive reduction to 
practice assumes that predictions made without physical creation will be 
accurate.90 It is therefore not clear that the doctrine should be allowed in 
                                                 
81 Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1376 (Fed. Cir. 1986). 
Constructive reduction to practice is supposed to be equal to actual reduction to practice. John 
Duffy, Reviving the Paper Patent Doctrine, 98 CORNELL. L. REV. 1359, 1366 (2013). 
Underlying the doctrine is an assumption of accuracy – that the disclosed invention will be 
function and that the inventor “has” the invention. Wheeler v Clipper Mower and Reaper Co., 
6 Fisher’s Patent Cases 1, 16. If a description does not work, it is arguably not constructively 
reduced to practice. See Cooper v. Goldfarb, 154 F.3d 1321, 1328 (Fed. Cir. 1998); Conover v. 
Downs, 35 F.2d 59, 60 (CCPA 1929). 
82 The number of patents in this field grew significantly in the early 20th century. E.g., 
David Katz, Proposal to Improve the Patent System, 17 J. PAT. OFF. SOC’Y 777, 780-81 
(1935). 
83 Eugene W. Geniesse, Adequate Description, 27 J. PAT. OFF. SOC’Y 784, 784 (1945). 
84 Geniesse, supra note 83, at 787 (“Illustrative examples in chemical cases serve the same 
purposes as do drawings in mechanical cases.”). 
85 Id. See also In re Borkowski, 422 F.2d 904, 908 (CCPA 1970) (“as we have stated in a 
number of opinions, a specification need not contain a working example if the invention is 
otherwise disclosed in such a manner that one skilled in the art will be able to practice it 
without undue experimentation.”). 
86 Harold C. Wegner, Patent Law Simplification and the Geneva Patent Convention, 14 
AIPLA Q.J. 154, 194 (1986). 
87 Joseph Rossman, The Rejection of Broad Chemical Claims, 14 J .PAT. OFF. SOC’Y 873, 
873 (1932). 
88 Schering Corp. v. Gilbert, 153 F.2d 428, 433 (1946). 
89 Seymore, supra note 77, at 282; Rossman, supra note 87, at 873. 
90 E.g., Cooper v. Goldfarb, 154 F.3d 1321, 1328 (Fed. Cir. 1998) 
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chemical patents, even if it was standard in mechanical patents. However, there 
are remarkably few records objecting to constructive reduction to practice in 
chemical patents.91 Instead, it quickly became clear that constructive reduction 
to practice was as acceptable for chemical patents as it was for mechanical 
patents.92  
 
…an applicant may base a [chemical] patent application wholly on 
speculation…without doing any actual work…In layman’s language 
this means that a patent can be secured on mere supposition without 
having actually invented or discovered anything.93 
 
The need for examples in chemical patents combined with the permissibility of 
constructive reduction to practice led to use of constructive reduction to 
practice in examples: prophetic examples. If a drawing of a never-built 
machine could be used to enable a mechanical invention, proponents of 
prophetic examples argued, then why not allow a never-conducted experiment 
to enable a chemical invention?94 
 
2. Prophetic Examples Become Patent Office Policy 
 
For the first 50 years of prophetic examples,95 the Patent Office had no 
official rules concerning the practice, but had an unofficial practice of allowing 
them. In 1980, the District of Delaware sharply criticized the Patent Office, 
stating that it 
 
can conceive of no reason for the PTO to countenance such a practice. 
In effect, the PTO is permitting itself to be misled by patent applicants 
                                                 
91 There are a small number of sources that point to the necessity of actual experiments in 
chemical patents. Rossman, supra note 87, at 874. 
92 Undue Breadth—Disclosure of Single Metal as Masking Material in Welding Operation 
Held Insufficient Basis to Support Claim Directed Broadly to ‘Material’, 29 J. PAT. OFF. 
SOC’Y 455, 458 (1947) (“Many patents are undoubtedly granted on structures proposed in 
drawings but which structures have never been actually made, and seemingly the practice does 
not forbid the same sort of presentation with respect to phenomena not predictable with 
certainty such as is found in chemistry…”). 
93 Geniesse, supra note 83, at 788. 
94 Rossman, supra note 8787, at 875 (citing an unnamed Board of Patent Appeals and 
Interferences case: “We know of no authority which denies protection when applicants may 
not have actually produced the compounds he claims as his invention…but which he has 
visualized as the reaction product of known materials. In the mechanical field protection is 
given to inventions which are constructively reduced to practice…The description of a new 
compound by its formula or name in terms of standard nomenclature is analogous to the 
description and drawing of a machine…Applicants have complied with these rules by 
[prophetically] telling how the compounds can be made and how they can be used.”). 
95 The earliest mention of prophetic examples I was able to find came from a case in 1927 
where the 6th Circuit noted that a patent’s reference to “certain grades of untreated cassava” 
might be “perhaps merely prophetic, because the record indicates that [the inventor] had not 
found any raw starch which would perform properly…” Perkins Glue Co. v. Holland Furniture 
Co., 18 F.2d 387, 387 (6th Circ. 1927). Prophetic examples may have been used earlier. 
 
during the process of granting a monopoly. Moreover, the public is 
mislead by such misrepresentations.96 
 
Shortly thereafter – and perhaps because of the criticism97 – the Patent Office 
made its first official statement on prophetic examples, adding them to the 
Manual of Patent Examination Procedure in 1981. The PTO originally inserted 
a provision stating that  
 
 Applicants must indicate which tests and examples are only 
simulated or predicted and which tests and examples have actually 
been carried out to permit the examiner to examine the same 
properly. Simulated or predicted tests are ‘paper’ examples and 
must not be confused with actual working examples. Working 
examples…must be written in the past tense…Paper examples, 
however…must be written in the present or future tense…98 
 
 … Clarity as to test results is essential because patent examiners 
have relatively little or no resources to test the veracity of 
representations made by applicants.99 
 
This provision was inserted with no advance notice100 or discussion.101 The 
provision dismayed some attorneys, who felt it restricted patent protection.102 
 
 After 9 months, the PTO withdrew most of the provision, leaving only the 
statements that prophetic examples are permitted in patent applications and 
that they must be described in the present tense while working examples are 
                                                 
96 Grefco, Inc. v. Kewanee Industries, Inc., 499 F.Supp. 844, 868 (D.Del. 1980). 
97 American Patent Law Association Midwinter Meeting – Committee Reports, 1983 
APLA 208, 209 (1983) (“Statements by the Court in Grefco…prompted the short lived 
January 1981 version of the MPEP §608.01(p) on ‘Simulated or Predicted Tests or 
Examples.’”). See also, Donald G. Dau, Chemical Names as Anticipation and Support, 70 J. 
PAT. & TRADEMARK OFF. SOC’Y 377, 394 (1988) (“It is rumored…that the deleted changes 
had been responsive to criticism of the PTO in Grefco Co. v Kewanee Industries…”). 
98 MPEP § 608.01(p), 104 (Rev. 5, Jan 1981), available at 
http://www.uspto.gov/web/offices/pac/mpep/old/E4R5_600.pdf. 
99 Id. 
100 Donald G .Daus, Chemical Names as Anticipation and Support, 70 J. PAT. & 
TRADEMARK OFF. SOC’Y 377, 394 (1988) (“The provisions had been inserted in the MPEP 
without advance notice. No ‘grandfather’ exceptions had been recited.”). 
101 Irwin M. Aisenberg, The Patent and Present of Working Examples, 23 IDEA 25, 25 
(1982) (complaining that this “fundamental alteration in disclosure requirements should clearly 
require an appropriate statutory enactment rather than an insert in the M.P.E.P.”). 
102 Id. at 27 (1982) (“it is not within the examiner’s domain to limit available or to 
challenge support of claim scope by differentiating between examples which reflect concluded 
experiments and those which do not. It is highly questionable whether an examiner even has a 
right to ask which examples are merely ‘paper’ examples….The Rules still fail to provide any 
authority for distinguishing between examples which reflect an actual reduction to practice and 
those which do not.”). 
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described in the past tense.103 Specifically, the provision prohibiting results in 
prophetic examples was removed, as was the exhortation for clarity and the 
explanation that patent examiners cannot test the veracity of statements in 
patents.104 The PTO did not clarify the reason for the change, stating only that 
the original provisions “went further than was intended.”105 
 
Though the PTO did not specify why it chose to permit prophetic 
examples, the original statement in the MPEP suggests that it may have been a 
question of administrative necessity. The PTO may simply not have the 
capacity to check whether an invention had been physically made. The PTO 
suggested as much in its original MPEP statement noting that examiners have 
“little or no resources to test the veracity of representations made by 
applicants.”106 Scholars have suggested that the PTO originally accepted the 
doctrine of constructive reduction to practice for the same reason.107 
 
3. Prophetic Examples in Recent Case Law 
 
The law of prophetic examples has stayed substantially static since 1981. 
The relevant provision in the MPEP has not changed.108 Case law has by and 
large simply pointed to the MPEP as a source of permission for prophetic 
examples. Most cases that address prophetic examples simply accept that the 
prophetic example supports the invention and include no discussion of the 
examples’ value or any controversies or doctrinal points. 109  
                                                 
103 MPEP, supra note 98, at § 608.01(a). 
104 Id. 
105 1038 OFFICIAL GAZETTE 100 (Nov. 5, 1981) (“The wording of the MPEP provisions 
prior to this amendment went further than was intended. The amended sections below spell out 
more clearly the Office’s position from the start.”). 
106 MPEP, supra note 98, at § 608.01(a). Alternatively, the PTO’s reluctance to question 
whether the application of a rule that worked for mechanical patents was appropriate for 
chemical patents may be a result of the insularity of the patent bar. See John Duffy, Rethinking 
Patent Law’s Uniformity Principle, 101 NW. L. REV. 1619, 1645 (2007) (exploring the 
consequences of the Federal Circuit’s exclusive jurisdiction on the insularity of patent law, but 
noting that even before the Federal Circuit “the patent bar was a recognized specialty and a 
somewhat insular community.”).  
107 Duffy, supra note 81, at 1370 (explaining that the PTO has “little or no ability to 
investigate the underlying physical reality of inventions.”). Moy’s Walker on Patents puts the 
matter more pointedly by noting that the doctrine is “an attempt to provide a theoretical basis 
for a problematic practice of the PTO…during examination the PTO does not inquire whether 
applicants have actually reduced their claimed inventions to practice. Thus, patents routinely 
issue on inventions that were not constructed as of the filing date.” § 8:93 Conceptual 
Inconsistencies – Constructive Reduction to Practice (4th ed. 2017). 
108 MPEP § 608.01(a) (9th ed. Rev. 07.2015, Nov. 2015). 
109 See, e.g., Phigenix Inc. v. Genentech Inc., 2016 WL 4172202, *1 (N.D.Cal. Aug. 8 
2016). (“[the patent] describes prophetic examples that predict that this phenomenon also 
occurs in breast cancer cells.”); Regeneron Pharmacueticals v. Merus, 2014 WL 6611510, at 
*18 (S.D.N.Y. 2014) (“Example 3 (a prophetic example), confirms human genomic DNA.”); 
Ex Parte Artemis Medical Inc., 2010 WL 4084621, *3 (BPAI 2010) (“Anderson’s Prophetic 
Example 2 describes the preparation of a copolymer obtained by polymerizing lactic acid and 
glycolide monomers.”); Ex Parte Ignatius Loy Britto, 2008 WL 2781982, *3 (BPAI 2008) 
 
 
Though it is well settled that prophetic examples can be used to satisfy the 
disclosure requirements, the issue still arises frequently, suggesting that 
litigants remain somewhat skeptical. This skepticism is not entirely unfounded. 
The Wands factors, which embody the seminal test for enablement, list the 
presence or absence of “working examples” as a factor in the analysis, but omit 
prophetic examples.110 Furthermore decision-makers, including the Board of 
Patent Appeals and Interferences (“BPAI”) and Patent Trial and Appeal Board 
(“PTAB”), will often hint that prophetic examples are not quite as good as 
working examples by prefacing prophetic evidence with a word suggesting 
hesitation, such as bemoaning the lack of “working or even prophetic 
examples.”111  
 
Overall, caselaw on prophetic examples remains sparse.112 An April 2017 
search for cases mentioning the term “prophetic example” uncovered only 52 
cases in Westlaw’s Federal Cases database and 46 and 12 cases from the Board 
of Patent Appeals and Interferences and Patent Trial and Appeal Board 
databases, respectively.113 Searches for “paper example” found few relevant 
cases, suggesting that the dominant terminology is “prophetic” rather than 
“paper.”  
 
II. THE CASE FOR PROPHETIC EXAMPLES 
 
There has never been any thorough examination of why we permit 
prophetic examples. Allowing fictional data in patents is, at first glance, a 
                                                                                                                                
(“Prophetic Examples 3 and 13 describe the use of PTFE-PES blend…”); Ex Parte David I. 
Gwynne et al., 2000 WL 33118608, *4 (BPAI 2000) (“The examiner points to Yelton’s 
prophetic example…which describes cloning and expression of a foreign polypeptide…”). 
110 In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).  
111 Enzo Biochem, Inc. v. Applera Corp., 2013 WL 3965305, *8 (D.Conn. 2013). See also, 
Ariad, 598 F.3d, at 1357. See also Takeda v. Handa, 2013 WL 9853725, *72 (N.D.Cal. 2013) 
(finding that the patent “does not contain any working examples…instead, all of the 
examples…[are] prophetic…”); Ex Parte Robert C. Lam, 2008 WL 503540, *3 (BPAI 2005) 
(“The only examples provided are two ‘prophetic’ examples”) (emphasis added); Ex Parte 
Katherine W. Klinger, 2006 WL 2523659, *2 (BPAI 2003) (“The application is devoid of 
working examples and/or models…However, as Appellants note…the Specification does 
include prophetic examples.”) (emphasis added). Similarly, courts have found prophetic 
examples based on actual experiments to be a particularly convincing flavor of prophetic 
example. E.g., Warner Lambert Co. v. Teva Pharmaceuticals USA, Inc., 2007 WL 4233015, 
*11 (D.N.J.) (“the ‘prophetic’ examples of the specification were based on actual experiments 
that were slightly modified in the patent to reflect what the inventor believed to be optimum, 
and hence, they would be helpful in enabling someone to make the invention.”).  
112 Rothschild v. Cree, Inc., 711 F.Supp.2d 173, 209 (D.Mass. 2010) (“There are very few 
cases dealing with prophetic examples in patents.”). 
113 The Board of Patent Appeals and Interferences (BPAI) and the Patent Trial and Appeal 
Board (PTAB”) are administrative bodies within the PTO that hear appeals of patent 
examinations and related issues. 35 U.S.C. 6(b). The BPAI was renamed the PTAB in 2012 (at 
which point the BPAI ceased to exist), and Westlaw indexes decisions from the boards in 
separate databases.  
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perplexing practice114 – and the scholarly literature on prophetic examples, 
though brief, is overwhelmingly negative.115 Nonetheless, there is a serious 
theoretical case to be made for the benefits of prophetic examples, and I make 
that case in this section. In doing so, I create a series of testable hypotheses that 
I evaluate empirically in Section III.  
 
The purpose of patents is to incentivize innovation.116 Inventors are 
motivated by the knowledge that they will receive patent exclusivity as a 
reward.117 Roughly speaking, stronger, bigger, and more effective patent rights 
increase this reward.118 The most convincing explanation for prophetic 
examples is that they help patentees, thereby strengthening the exclusivity 
incentive for innovation. In Part A, below, I hypothesize that prophetic 
examples can lead to patents that are broader and filed earlier than would be 
possible in the absence of prophetic examples.  
 
To make the case for prophetic examples, it is not enough that they help 
patentees. They must also not be harmful. In Part B, I make explicit two 
additional requirements that must be satisfied to justify the use of prophetic 
examples. First, prophetic examples should not impede innovation in the area 
described by the patent. Second, prophetic examples should be consistent with 
the underlying logic of patent law.  
 
A.  Potential Benefits 
 
1. Earlier-Filed, Broader Patents 
 
Patent applications with prophetic examples can be filed earlier than 
applications with working examples because writing a prophetic example is 
faster than conducting even the simplest of real experiments.119 Moreover, real 
experiments might not work or might produce unexpected data, necessitating a 
potentially time-consuming change to protocols or development of a new 
procedure. Prophetic examples do not have this potential. Thus, applicants who 
choose prophetic examples will be able to file a patent application earlier than 
                                                 
114 For example, one court complained that it “can conceive of no reason for the PTO to 
countenance such a practice.” Grefco, Inc. v. Kewanee Industries, Inc., 499 F.Supp. 844, 868 
(D.Del. 1980). 
115 See all references cited in note 10, supra. 
116 E.g., Diamond v. Chakrabarty, 447 US 303, 307 (1980). 
117 See, e.g., Peter S. Menell & Suzanne Scotchmer, Intellectual Property Law, in 2 
HANDBOOK OF LAW AND ECONOMICS 1473, 1476-78 (A. Mitchell Polinsky & Steven Shavell 
eds., 2007). 
118 E.g., Robert P. Merges and Richard R. Nelson, On the Complex Economics of Patent 
Scope, 90 COLUM. L. REV. 839, 840 (1990). 
119 As one guide notes: “Situations may arise when an inventor has a great idea but has no 
time for lengthy experimentation or time-consuming data collection…In such instances, the 
filing of a prophetic patent application may be the solution…” JOSEPH P. KENNEDY, ET AL, 
HOW TO INVENT AND PROTECT YOUR INVENTION: A GUIDE TO PATENTS FOR SCIENTISTS AND 
ENGINEERS, § 5.5.3 (2012). 
 
applicants who choose to conduct experiments, a particular advantage in 
competitive and fast-moving fields.120  
 
Prophetic examples also help applicants obtain broader patents. Patents 
must teach others how to make and use their inventions, and a broader patents 
covering more material require more teaching. To get a patent on one 
molecule, one experimental protocol is generally enough to teach how to 
synthesize the molecule.121 To get a patent on many different molecules, many 
synthesis protocols will be needed. Thus, patent drafters will try to include 
more examples to support broader claims.122 Prophetic examples are 
instrumental to this function.123 Prophetic examples also allow applicants to 
seek a broad patent without conducting expensive experiments, which reduces 
the cost of patents. 
 
The following example illustrates how prophetic examples allow for 
broader, cheaper, and earlier-filed patents. Para-dichlorobenzene, the molecule 
historically used in scented deodorizers, was suspected to be toxic.124 To solve 
this problem, a pair of inventors discovered a new molecule that could be 
combined with various scents and would slowly releases those scents over time 
                                                 
120 Practicing Law Institute, How to Write a Patent Application, 17-36 (2016). See also 
ROBIN FELDMAN, RETHINKING PATENT LAW, 160 (2012); Tom Brody, CLINICAL TRIALS, 837 
(2016) (“Prophetic examples can be [used if]…the inventors did not have enough time to 
complete, or even initiate, any of the relevant experiments before the patent application was 
filed.”). 
121 MPEP § 2164 (explaining that “A single working example in the specification for a 
claimed invention is enough to preclude a rejection which states that nothing is enabled since 
at least that embodiment would be enabled. However, a rejection stating that enablement is 
limited to a particular scope may be appropriate.”). 
122 See, e.g., Enzo Biochem. Inc. v. Calgene, Inc., 188 F.3d 1362, 1374 (Fed. Cir. 199) 
(holding that the patent was not valid because “the number of working examples provided in 
the specifications were ‘very narrow,’ despite the wide breadth of the claims at issue…”). 
123 See, e.g., Brody, supra note 120, at 837; Troy Groetken, IP: Sufficiency of Disclosure 
and the Great Divide Between U.S. and Europe, INSIDE COUNSEL (February 26, 2014), 
available at http://www.insidecounsel.com/2014/02/26/ip-sufficiency-of-disclosure-and-the-
great-divide (“[M]any times, the actual examples provided do not provide the same level of 
breadth as the written word descriptive sections attempting to broaden the claimed invention. 
To overcome this, a number of prophetic examples are sometimes included in the 
specification”); WILLIAM G. KONOLD, WHAT EVERY ENGINEER SHOULD KNOW ABOUT 
PATENTS, 54 (1989); William B. Slate, The Real Security of Continuation-in-Part 
Applications, 83 J. PAT. & TRADEMARK SOC’Y 551, 554 (2001); PRACTICING LAW INSTITUTE, 
BIOTECHNOLOGY LAW: BIOTECHNOLOGY PATENTS AND BUSINESS STRATEGIES IN THE NEW 
MILLENNIUM, 359 (2002). For example, in Synthes v. Spinal Kinetics, the Federal Circuit held 
that disclosure of one species in an unpredictable field was insufficient support for a broad 
genus. 734 F.3d 1332, 1334 (Fed. Cir. 2013). Following this case, practice guides 
recommended that to “avoid or minimize problems such as those in…Synthes…the applicant 
could have included prophetic examples…” Helene C. Carlson and Gaby L. Longsworth, 
Strengthening Pending and Future Application Portfolios in Advance of Potential Attack in 
AIA Proceedings, Pharmaceutical Law & Industry Report (April 3, 2015). 
124 U.S. Patent No. 4,842,853, col. 1, ll. 15-20, 34-44 (issued June 27, 1989). 
 Freilich 19 
– useful for products like air fresheners.125 If the inventors had wanted a 
narrow patent covering only one type of scent, including one example in the 
patent might have been enough. However, the inventors sought a broader 
patent – covering slow release of many different “fragrant substances.”126 
Thus, it was necessary to include more examples in the patent. Perhaps lacking 
the time or money to conduct experiments with many different types of 
fragrant substances, the inventors wrote 7 prophetic examples with instructions 
for how to make these compositions.127 These included ingredients, amounts, 
and mixing instructions for making scents such as “Sea Breeze,” “Lilac 
perfume oil,” and “Lily of the valley.”128 Though these protocols were all 
predictions, rather than tested conclusions, but they were enough for the 
examiner to grant the broad patent. 
 
Finding an alternative to carcinogenic deodorizers is a worthwhile 
innovation of the type we hope to incentivize with patents. If these inventors 
could only have gotten a narrow patent covering one scent, it might not have 
been enough of a reward to incentivize the initial invention. Prophetic 
examples allowed the inventor to get a broader patent. Without prophetic 
examples, this technology may never have been made available to the public. 
 
2. Special Situations 
 
Prophetic examples may be useful in a variety of situations where the 
inventor is not able to conduct a real experiment. In these situations, prophetic 
examples create exclusivity where it would not otherwise be available, 
potentially incentivizing innovation. One such situation occurs when a small 
company cannot afford to conduct a large number of experiments (to get a 
broader patent) before a patent is filed. Prophetic examples may help equalize 
the availability of broad patents between companies with resources and those 
without.129 
 
Another such special situation where prophetic examples are needed for 
filing a patent is the catch-22 situation where a funder will not provide capital 
without a patent, but the experiments necessary to get the patent cannot be 
done without funding. Using prophetic examples to file before the experiment 
is actually conducted also helps patentees who risk losing the ability to patent 
                                                 
125 Id. 
126 Id. 
127 Id. at col. 3, l. 18 – col. 4, l. 53. 
128 Id. at col. 3, ll. 19, 40, 65.   
129 See Aisenberg, supra note 101, at 30 (explaining that prophetic examples are important 
because “an individual inventor in the chemical arts is already hard put to perform or obtain 
testing often required to procure a reasonable scope of patent protection.”). There is concern in 
other contexts that the patent system disadvantages small companies and individual inventors. 
E.g., Clark Asay, Patenting Elasticities, 91 S. CAL. L. REV. (forthcoming 2018); Polk Wagner 
& David Abrams, Poisoning the Next Apple? How the America Invents Act Harms Inventors, 
65 STAN. L. REV. 517, 534 (2013). 
 
if they obtain data before filing a patent. This occurs because an inventor’s 
own public disclosure about the invention can bar him from later filing for a 
patent on the invention.130 What precisely constitutes a public disclosure is 
contextual, but it may occur if samples are sent out for testing131 or 
manufacturing.132 A particularly contentious issue is the question of clinical 
trials, where a drug must be distributed to doctors and patients and certain 
disclosures must be made. Though appropriate confidentiality agreements can 
prevent clinical trials on a drug from blocking later patenting of the drug, it is a 
sufficiently problematic issue that the question is frequently litigated.133  
 
Moreover, there may be regulatory obstacles to conducting real 
experiments. It is conventional in the pharmaceutical industry to file patents on 
treatments that show promise in in vitro – lab based – experiments.134 It can 
take years, and hundreds of millions of dollars, to obtain FDA permission for 
human experiments and to conduct those experiments.135 It is risky to make 
this investment without patent protection. Thus, pharmaceutical companies 
generally require a patent early in a drug’s lifecycle and, crucially, before 
human data can possibly be obtained.136 Though it is not strictly necessary to 
include human data to obtain a patent on a drug, patents lacking human data 
have occasionally been invalidated, therefore pharmaceutical companies prefer 
to include human trials.137 
                                                 
130 35 U.S.C. § 102. 
131 E.g., Pronova Biopharma Norge AS v. Teva Pharmaceuticals USA, Inc., 549 Fed. 
Appx. 934, 939 (2013) (finding that the plaintiff’s patent was invalid because the company had 
sent samples to a consultant for testing and promotional purposes before the patent application 
was filed). 
132 The Federal Circuit has recently clarified that a manufacturing contract to produce a 
product is not a disclosure that bars later patenting assuming appropriate confidentiality 
requirements are met, but this has historically been an area of concern for innovators. The 
Medicines Co. v. Hospira, Inc., (Fed. Cir. July 11, 2016) 
133 See, e.g., Dey, L.P., v. Sunovion Pharmaceuticals, Inc., 715 F.3d 1351, 1358 (2013) 
(explaining that “courts have routinely rejected the argument that such an arrangement [clinical 
trials] strips the trial of confidentiality protection or renders it accessible to the public.”). See 
also Bayer Schering Pharma AG v. Barr Labs, Inc., 2008 WL 628592, at *11-12 (D.N.J. Mar. 
3, 2008); Eli Lilly & Co. v. Zenith Goldline Pharm., Inc., 364 F.Supp.2d 820, 273 (S.D.Ind. 
2005), In re Omeprazole Patent Litig., 490 F.Supp.2d 281, 508 (S.D.N.Y. 2007), aff’d on other 
grounds, 536 F.3d 1351 (Fed. Cir. 2008); Janssen Pharmaceutical N.V. v. Eon Labs Mfg., Inc., 
374 F.Supp.2d 263, 276 (E.D.N.Y. 2004), aff’d 134 Fed.Appx. 425, 430 (Fed. Cir. 2005). 
134 Rebecca S. Eisenberg, The Role of the FDA in Innovation Policy, 13 MICH. 
TELECOMM. & TECH. L. REV. 345, 348 (2007). 
135 Joseph A. DiMasi, Ronald W. Hansen, & Henry G. Grabowski, The Price of 
Innovation: New Estimates of Drug Development Costs, 22 J. HEALTH ECON. 151, 162 (2003). 
136 Eisenberg, supra note 134, at 348. 
137 Note that patents are not invalidated solely for lacking human data, but rather for an 
insufficient connection between the claimed utility of the invention and the evidence in the 
specification. See In re ‘318 Patent Infringement Litigation, 583 F.3d 1317, 1327 (Fed. Cir. 
2009); Rasmusson v. Smithkline Beecham Corp., 413 F.3d 1318, 1323-25 (Fed. Cir. 2005); In 
re Brana, 51 F.3d 1560, 1566-68 (Fed. Cir. 1995) (reversing the BPAI’s rejection of the patent 
and explaining that “FDA approval, however, is not a prerequisite for finding a compound 
useful within the meaning of the patent laws.”). 
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For instance, the patent applicant in Bone Care International sought a 
patent on a method of treating osteoporosis using the molecule 
doxercalciferol.138 The applicant had created a detailed plan for a clinical trial 
of this drug, but, probably for the reasons described above, could not wait until 
completion of all trials to file the patent.139 The applicant therefore filed a 
patent with working examples reporting stage I and stage II clinical trials and 
several prophetic examples detailing a double-blind trial and its (prophetic) 
results.140 
 
A twelve-month double-blind placebo-controlled clinical trial is conducted 
with thirty-five men and women…Analysis of the clinical data shows that 
[doxercalciferol] increases…intestinal calcium absorption, as determined 
by direct measurement…141 
 
Because the PTO permits prophetic examples, the applicant could use the 
results of the clinical trial to support the patentability of the compound – even 
before the clinical trial had been conducted.142 Without prophetic examples, 
the applicant may not have felt secure enough to invest in the necessary 
clinical trials, depriving the public of a valuable drug. With prophetic 
examples, Bone Care filed the patent, got FDA approval, and has sold millions 
of doses of the drug under the brand name Hectorol®.143  
 
In situations of the types outlined above, it is simply not practical for an 
inventor to conduct real experiments. This means that, were prophetic 
examples not allowed, these inventors might not be able to get a patent. 
Without prophetic examples, we might see reduced innovation from small 
companies or those in the pharmaceutical space.  
 
* * * 
 
The case for prophetic examples is founded on their benefits to patentees. 
The sections above describe specific ways in which prophetic examples help 
patentees. From this, we can extract several testable hypotheses. Prophetic 
examples should allow patents to be (1) broader; (2) filed earlier; and (3) be 
particularly useful in specific situations such as for patents filed by small 
                                                 
138 Bone Care Intern., LLC v. Pentech Pharmaceuticals, Inc., 862 F.Supp.2d 790, 800 
(N.D.Ill. 2012). 
139 Id. at 798. 
140 U.S. Patent No. 5,602,116, col. 11, l. 40 – col. 12, ll. 5 (issued Feb. 11, 1997). 
141 Id. 
142 During a later trial, defendants challenged whether the prophetic example adequately 
enabled the relevant claim. The court found that it did and that the claim was valid. Bone Care, 
862 F.Supp.2d at 800. 
143 Genzyme Corporation, HECTOROL – doxercalciferol injection, solution, 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021027s015lbl.pdf (Bone Care 
International sold the product to Genzyme). 
 
entities, experiments that are expensive and cannot be done without funding, 
and experiments involving clinical trials.  
 
B.  Potential Costs 
 
To be justifiable, prophetic examples must help patentees, but it is not 
enough for them to merely help patentees. The underlying assumption in the 
case for prophetic examples is that they help patentees in a way that is not 
harmful to the patent system more broadly. This assumption has two main 
components, each of which is discussed below. 
 
1. Chilling Downstream Research 
 
Prophetic examples might help patentees file earlier, broader patents. 
However, it is far from clear that these broader, earlier filed patents are 
actually socially beneficial.144 Broad, early filed patents are supported by 
adherents of the “prospect” theory of patent law145 who argue that such patents 
allows patentees to coordinate technological development in that area.146 This 
prevents wasteful races to invent and reduces transaction costs during 
downstream development.147 These are all potential benefits of prophetic 
examples. 
 
However, some scholars worry that overly broad patents reduce 
competition and block downstream innovation,148 and that early-filed patents 
reflect less developed inventions and therefore lead to patents that are more 
vague, useless, or, if useful, are never commercialized.149 The problem with 
such patents is that they might effectively prevent others from working in the 
areas surrounding the patent. First, while the patent is in force, others cannot 
do their own experiments in the area covered by the patent - even if the 
                                                 
144 See Christopher A. Cotropia, The Folly of Early Filing in Patent Law, 61 HASTINGS 
L.J. 65, 67 (2009); Lemley, supra note 10 at 245; Ted Sichelman, Commercializing Patents, 
62 STAN. L. REV. 341, 343 (2010). 
145 Edmund W. Kitch, The Nature and Function of the Patent System, 20 J.L. & ECON. 
265, 266 (1977).  
146 Samuel Oddi, Un-Unified Economic Theories of Patents – The Not-Quite-Holy Grail, 
71 NOTRE DAME L. REV. 267, 275 (1996). 
147 Kitch, supra note 145, at 267. It also causes patents to expire earlier, a potential benefit 
to society. See John Duffy, Rethinking the Prospect Theory of Patents, 71 U. CHI. L. REV. 439, 
440 (2004). 
148148 E.g., Peter Menell, The Challenges of Reforming Intellectual Property Protection for 
Computer Software, 97 COLUM. L. REV. 2644, 2646 (1994); Arti K. Rai, Fostering Cumulative 
Innovation in the Biopharmaceutical Industry, 16 BERKELEY TECH. L.J. 813, 831 (2001). 
149 See, e.g. Kimberly A. Moore, Worthless Patents, 20 BERKELEY TECH. L.J. 1521, 1540 
(2005) (finding that pharmaceutical and biotechnology patents were abandoned more often 
than mechanical patents, and suggesting that “these industries rush to patent new compounds 
and genes (and their methods of manufacture) before knowing whether those compounds have 
great utility or commercial viability.”). 
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prophetic examples do not work.150 Even after the patent has expired or been 
abandoned, it might still chill research in that area because others cannot get a 
patent on an invention disclosed in or rendered obvious by a prophetic 
example.151 Patents are given only for inventions that are new and nonobvious, 
therefore material that is disclosed, and everything obvious based on that 
disclosed material, is no longer patentable.152 This is true even if the subject of 
the disclosure was never physically created.153 We know that companies make 
strategic disclosures in their patents for the express purpose of preventing 
competitors from obtaining patents.154 Prophetic examples may be one form of 
such disclosure. 
 
For instance, in Ex Parte Botond Banfi, the inventors sought to patent the 
use of iodide to treat microbial diseases.155 The PTO rejected the application 
on the grounds that the invention was not new because it had been disclosed in 
a prior patent.156 The prior patent had indeed disclosed use of iodide, but in a 
prophetic example describing the treatment of asthma (which is not a microbial 
disease).157 The prophetic example is: 
 
A 45 year old female with a history of severe asthma with a morning 
peak flow of less than 3 l/sec is treated with…iodide in an aerosol 
formulation, 2 mg three times daily continuously. After a week of 
                                                 
150 One inoperative embodiment does not mean that the patent is invalid. E.g., In re 
Angstadt, 537 F.2d 498, 502-503 (CCPA 1976). 
151 35 U.S.C. §§ 102-103. 
152 For novelty: Ex Parte Natalya B. Danilova, 2008 WL 4768088, at *4 (BPAI 2008) (“As 
to the matter of Bower [an anticipating reference] being a ‘paper patent’, assuming arguendo 
that this is in fact the case, the patent is nonetheless useful under 102 and 103 as prior art. Note 
that a patent need not be commercially practical to be anticipatory.”). For criticisms of this 
rule, see e.g., Sean B. Seymore, Reinvention, 92 NOTRE DAME L. REV. 1031, 1031 (2017). 
However, in order to anticipate a later patent, the prophetic example must be enabled. For 
obviousness: Ex Parte Marek Z. Kubin and Raymond G. Goodwin, 2007 WL 2070495, *2 
(BPAI 2007) (finding obviousness based on a reference, which “expressly teaches through a 
prophetic example how to ‘isolate the cDNA clone using mAb C1.7, screening the protein 
expression in the cell transfected with the cDNA library and cloning a corresponding cDNA 
into a plasmid for sequencing.’”). 
153 Ex Parte Harry Fisch, 2009 WL 2760600, *6 (2009) (“Appellant also argues that the 
test study designed by MacLean is a prophetic example…However, anticipation does not 
require actual performance of suggestions in a disclosure, only that those suggestions be 
enabling to a skilled artisan. Therefore this argument is not persuasive…”). Or, for 
obviousness, even if the disclosure was not enabled. MPEP § 2121.01.  
154 E.g. Scott Baker and Claudio Mezzetti, Disclosure as a Strategy in the Patent Race, 48 
J. L. & ECON. 173, 174 (2005); Oren Bar-Gill and Gideon Parchomovsky, The Value of Giving 
Away Secrets, 89 VA. L. REV. 1857, 1857 (2003); Rebecca Eisenberg, The Promise and Perils 
of Strategic Publication to Create Prior Art: A Response to Professor Parchomovsky, 98 
MICH. L. REV. 2358, 2367 (2000); Gideon Parchomovsky, Publish or Perish, 98 MICH. L. REV. 
926, 927 (2000); Seymore, supra note 10, at 1058. 
155 Ex Parte Botond Banfi, 2015 WL 6407275, *1 (Patent Tr. & App. Bd. 2015). 
156 Id. 
157 Id.  
 
treatment the peak flow improves to 6 l/sec.158  
 
Although the example was both prophetic and did not actually involve a 
microbial disease, the court reasoned that it inherently disclosed use of iodide 
to kill microbes. If someone had used the technique, it would have incidentally 
resulted in the removal of microbes from the throat, even though that was not 
the main purpose of the treatment.159  
 
Though there is no evidence that this example was included for the purpose 
of defensive disclosure, the example shows how use of a prophetic example 
can prevent patenting in a wide area around the patent. The prior patentee 
never tried using iodide to treat asthma (indeed, it is not clear that the 
technique would work),160 but the patent effectively prevented others from 
getting later patents on iodide to treat completely different respiratory illnesses. 
Innovators are scared away from research in areas near prophetic examples 
either because they believe that someone has already tried the technique or 
because they worry that they will not be able to get a patent themselves.161 Any 
defense of prophetic examples must balance their benefits to patentees against 
this potential problem.  
 
2. Inaccurate and Misleading 
 
The second potential cost of prophetic examples lies in their ability to 
satisfy the enablement and written description doctrines. As part of the patent 
disclosure, prophetic examples need to both teach other scientists how to make 
and use the invention and help inventors prove possession of the invention.162 
It is only intellectually coherent to allow prophetic examples to serve these 
functions if they are actually understood by scientists and if they are accurate 
predictions.  
 
To illustrate, if prophetic examples are used to teach scientists how to make 
and use an invention, then they must in fact be able to do so. If prophetic 
                                                 
158 U.S. Patent No. 6,890,920, Example E (Issued May 10, 2005) 
159 Banfi, 2015 WL at *3. These “inherency” rejections are made when the examiner relies 
on “the inherent teaching of a prior art reference.” In re Napier, 55 F.3d 610, 613 (Fed. Cir. 
1995); MPEP § 2112.  
160 There were several articles on the use of potassium iodide to treat asthma published in 
the 1950s and 60s, but the technique does not appear to have caught on. See, e.g., WB Casey, 
On the Use of Iodide of Potassium in Asthma; Historical Document, 12 ANN. ALLERGY 728-29 
(1954). 
161 Though not in the context of prophetic examples, a scientist complained that “lazy 
people sit in their office and say ‘we should do this’ and the next minute they write a stupid 
invention disclosure and submit it…the problem is such people rarely complete these 
projects…[and] someone who has the same idea will…find the patent application and assume 
its been done before. I have seen personally many great ideas not being pursued because of 
this.” Ouellette, supra note 10 at 564. See also Benjamin Roin, Unpatentable Drugs and the 
Standards of Patentability, 87 Tex. L. Rev. 503, 545 (2009). 
162 35 U.S.C. § 112. 
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examples describe protocols that are entirely incorrect, then the patent reader 
cannot rely on them for instruction on how to make the invention. Similarly, if 
scientists are confused or misled by prophetic examples, then they do not 
actually teach scientists anything. Further, if prophetic examples are used to 
prove that the inventor had possession of the invention they must again be 
accurate predictions. If the inventor’s predictions are incorrect, it is doubtful 
that the inventor actually had possession of the invention described by those 
same predictions. In addition, once a patent is granted, prophetic examples are 
presumed to be accurate.163 The presumption is only reasonable if prophetic 
examples are in fact likely to be accurate.164 
 
At stake is not only whether patent doctrine is satisfied. The patent’s 
disclosure is also supposed to promote innovation.165 The standard explanation 
is that scientists get new technical information from patents and then use that 
knowledge to improve the technology or make their own inventive leaps.166 If 
the information in patents is confusing to these scientists or is simply 
inaccurate, then it is much harder for patents to promote innovation through 
disclosure. 
 
At present, we do not know if prophetic examples reflect accurate 
predictions. Some have suggested that prophetic examples are not accurate,167 
but the suggestion has not been discussed in depth nor has it been tested 
empirically. We similarly do not know if prophetic examples are understood 
by scientists, and again, some have suggested that they are not.168 Ninety-one 
percent of industry scientists read patents.169 If prophetic examples are 
inaccurate and misunderstood, it presents a major challenge to the enablement 
and written description requirements.  
 
* * * 
In order to be justifiable, prophetic examples must help patentees. But they 
must also do more: prophetic examples must (1) avoid chilling downstream 
research and (2) be both accurate and non-misleading. 
                                                 
163 Atlas Powder, 750 F.2d at 1577 (“The burden is on one challenging validity to show by 
clear and convincing evidence that the prophetic examples together with other parts of the 
specification are not enabling.”). 
164 There are other reasons to have a presumption of validity, including administrative 
simplicity and predictability for patentees. Nonetheless, the presumption is dubious if its 
underlying assumption is not correct. 
165 Kewanee Oil Co. v. Bicron Corp., 416 US 470, 481 (1974). 
166 Id. (“[the] disclosure, it is assumed, will stimulate ideas and the eventual development 
of further significant advances in the art.”). 
167 E.g., Sean B. Seymore, The Teaching Function of Patents, 85 NOTRE DAME L. REV. 
621, 632 (2010). Granted patents are presumed to be enabled and adequately described, and 
the challenger has the burden of proving that that they are not. E.g., Impax Labs. Inc. v. 
Aventis Pharm. Inc., 468 F.3d 1366, 1383 (Fed. Cir. 2006). 
168 Lisa Larrimore Ouellette, Who Reads Patents?, 35 NATURE BIOTECHNOLOGY 421, 423 
(2017). 
169 Id. at 421 (only 78% of academic scientists read patents). 
 
  
III. THE EMPIRICS OF PROPHETIC EXAMPLES: A NOVEL STUDY 
 
Given the importance of prophetic examples to several fundamental 
elements of the patent system, competing justifications and criticisms, and the 
extreme dearth of scholarship on the topic, it is important to know more about 
prophetic examples. This Section describes an empirical study of prophetic 
examples across all electronically published U.S. patents and applications. The 
study asks two primary questions. First, how prevalent are prophetic 
examples? Are they sufficiently numerous to affect patents and innovation, or 
are they merely an unusual – but uncommon – feature of patent law? Second, 
can prophetic examples be justified?  
 
A.  Study Design 
1. Populations 
 
Unless otherwise specified, patents were issued between 1976170 and June 
2017, and applications were filed between 2001171 and June 2017. I collected 
data for all granted patents and applications during this period. Although the 
data reported are drawn from a population, not a sample, I include tests for 
statistical significance in the event that readers want to extrapolate from the 
data to similar patents, for example, those from other years.172 
 
The patents were bulk downloaded and a variety of information was 
collected about each of these patents including the priority,173 filing,174 and 
issue dates,175 the number of claims,176 and the number of forward and 
backwards citations,177 whether the patent is a continuation178 or divisional,179 
                                                 
170 The USPTO full text database only covers 1976-onward. 
171 The USPTO’s application database only covers 2001-onward. 
172 I draw this strategy from John R. Allison & Lisa Larrimore Ouellette, How Courts 
Adjudicate Patent Definiteness and Disclosure, 65 DUKE L.J. 609, 629 (2016). As noted by 
Allison and Ouellette, because this study involves a population, coefficients may be 
meaningful even if they are not statistically significant – “any observed differences in a 
population are real ones.” Id.  
173 The filing date of the earliest application to which the studied patent or application can 
claim benefit. E.g., PowerOasis, Inc. v. T-Mobile USA, Inc., 552 F. 3d 1299, 1306 (Fed. Cir. 
2008). 
174 The date on which the studied application was filed. 37 C.F.R. § 1.741. 
175 The date on which the studied patent issued. MPEP § 1309. 
176 Each patent and application concludes with one or more claims which “particularly 
point out and distinctly claim the invention.” 35 U.S.C. § 112. Some scholars suggest that 
patents with more claims are broader or more important. E.g., Jean O. Lanjouw and Mark 
Shankerman, Patent Quality and Research Productivity: Measuring Innovation with Multiple 
Indicators, 114 THE ECONOMIC JOURNAL 441, 448 (2004). 
177 Forward citations are the number of times that the studied patent has been cited by 
other patents (note that this does not include citations to the application or citations by non-
patent literature). This is a rough measure of the importance of the invention. Id. Backward 
citations are the number of sources that are cited by the studied patent (both those listed by the 
applicant and those added by the examiner). Some scholars suggest that backward citations are 
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IPC classifications,180 and specification length.181 This information was 
obtained from patents downloaded from the USPTO’s Patent Grant Full Text 
Database, hosted by Reed Tech.182 Data on patent expiration,183 maintenance 
fees,184 and entity size185 was obtained from the USPTO.186  
 
2. Identifying Prophetic Examples 
 
Each patent was analyzed to determine if it contained an examples section, 
and, if so, the section was broken down into individual examples.187 This 
strategy excluded patents having no examples or integrating examples into the 
text of the patent, which is a limitation of the methodology.188 
 
                                                                                                                                
correlated with patent value and perhaps breadth, though any correlation would be indirect. 
E.g., Dietmar Harhoff et al., Citations, Family Size, Opposition and the Value of Patent Rights, 
1596 RES. POL’Y 1, 8 (2003).  
178 A continuation application has the same specification as the prior application, and uses 
the same priority date, but contains different claims. U.S. Water Services, Inc. v. Novozymes 
A/S, 843 F. 3d 1345, 1348 (Fed. Cir. 2016). Continuations can be used either to continue 
prosecution when the examiner does not grant the original application or to file several patents 
from the same base application, indicating that the applicant wants a portfolio of patents 
covering the area. Mark A. Lemley & Bhaven Sampat, Examining Patent Examination, 2010 
STAN. TECH. L. REV. 2, 16 (2010).  
179 A divisional application, like a continuation, has the same specification and the prior 
application and uses the same priority date, but contains different claims. Unlike a 
continuation, a divisional carves pieces off of the original application after the original 
application was found to contain more than one invention (each patent application may cover 
only one invention). 37 C.F.R. § 1.142; MPEP § 201.06. 
180 International Patent Classifications (IPC) are a common classification system to group 
patents by the nature of the claimed technology. Guide to the International Patent 
Classification (2017), 
http://www.wipo.int/export/sites/www/classifications/ipc/en/guide/guide_ipc.pdf. 
181 Specification length is the number of words in the patent, excluding the abstract and the 
claims.  
182 Reed Tech, USPTO Data Sets; Patent Grant Red Book (2017), available at 
http://patents.reedtech.com/pgrbft.php. 
183 Patents expire either at the end of their 20-year term or earlier if maintenance fees are 
not paid. 37 C.F.R. § 1.362. 
184 Id. 
185 Inventors are classified as either “large”, “small”, or “micro” entities, depending on the 
nature of the organization and the number of employees. 37 C.F.R. § 1.27 (defining small 
entities); 37 C.F.R. 1.29 (defining micro entities). 
186 United States Patent and Trademark Office, USPTO Bulk Downloads: Patent 
Maintenance Fees (2015), available at https://www.google.com/googlebooks/uspto-patents-
maintenance-fees.html#1981-present. Because micro entity status has only been available as of 
2013, micro entities are counted as small entities. Additionally, the USPTO maintenance fee 
records list entity size as of the date the maintenance fee was paid, which may be different 
from entity size as of the date the patent was filed. This study sought to identify entity size as 
of the date the patent was filed, thus, where the USPTO recorded a change from small to large 
entity for purposes of payment of maintenance fees, the entity was counted as a small entity. 
187 Full text of algorithm on file with author. 
188 See Figure 1 for data on how many patents with examples were identified using this 
strategy. 
 
Prophetic examples were identified by exploiting a USPTO grammar 
requirement: prophetic examples must be written in the present tense, while 
working (non-prophetic) examples should be written in the past tense.189 
Prophetic examples should be entirely in the present tense, as judges have 
warned against mixing past and present tense in an example.190 Further, 
examples written in the present tense are “presumed to be prophetic.”191 Where 
examples consist of numbers only, and therefore have no tense, the Patent 
Office assumes that the numbers are not prophetic.192 
 
Although it is impossible to verify whether patent drafters are correctly 
classifying experiments, the penalty for describing prophetic results in the past 
tense is high; therefore there is reason to believe that the self-classification is 
accurate. Representing a prophetic example as if it were actually conducted 
may result in a finding of inequitable conduct, rendering the entire patent 
unenforceable.193 There is no penalty for representing a working example as a 
prophetic example, in the present tense. However, I expect that this is 
uncommon for several reasons. First, patent drafting guides instruct that the 
past tense be used for working examples.194 Second, courts assume that 
examples written in the present tense are prophetic,195 and this has certain 
disadvantages if the example is in fact working.196 Third, most patents with 
prophetic examples also contain some examples written in the past tense, and it 
would be surprising if a patent drafter switched to the past tense for some 
working examples but left others in the present tense. 
 
 To validate the methodology, a patent agent manually reviewed a 
random sample of 100 examples and classified the examples as prophetic or 
non-prophetic. The patent agent identified 9 errors in the algorithm’s 
                                                 
189 MPEP § 2004 (“Paper or prophetic examples should not be described using the past 
tense.”). 
190 Hoffmann-La Roche, Inc. v. Promega Corp., 323 F.3d 1354, 1374 (Fed. Cir. 2003) 
(Newman, J., dissenting) (characterizing the majority’s approach for concluding why prophetic 
examples in the past tense constituted inequitable conduct). 
191 Ex Parte Vinod Sharma and Walter H. Olson, 2010 WL 2694700, *3 (BPAI 2010). See 
also Ex Parte Marlene Schwartz and Robert Richard, 2008 WL 2463016, *8 (BPAI 2008) 
(“Since the examples were written in the present tense, they were presumed prophetic and do 
not represent actual evidence.”). 
192 E.g. Ex Parte Nobutaka Jujimoto and Masafumi Okamoto, 2013 WL 649554, *1 
(PTAB 2013) (“Applicant relies on data on page 22 of the Specification. We assume that the 
data is a result of actual (as opposed to prophetic) examples.”); Ex Parte Mikael Schulsky, 
2009 WL 2810323, *3 (BPAI 2009) (“The specification and drawings include data…We 
assume the data is not based on prophetic examples.”). 
193 E.g. Novo Nordisk v Bio-Technology General, 424 F.3d 1347, 1361 (Fed. Cir. 2005). 
194 E.g., SAMUEL J. SUTTON, DAVID G. CONLIN, RICHARD L. SCHWAAB, PATENT 
PREPARATION & PROSECUTION PRACTICE 9.16 (1976). 
195 E.g., Ex Parte Michael Prencipe and Sayed Ibrahim, 2012 WL 5387521, *7 (PTAB 
2012); Ex Parte Marlene Schwarz and Robert Richard, 2008 WL 2463016, *8 (BPAI 2008) 
(“Since the examples were written in the present tense, they are presumed prophetic and do not 
represent actual evidence…”). 
196 Most notably, the Wands factors. In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988). 
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classification. Of these errors, the algorithm classified a working example as 
prophetic 3 times and a prophetic example as working 6 times. 
 
 Once prophetic examples are identified, they can be counted. There are 
multiple equally compelling ways to count prophetic examples: 
• Number of prophetic examples per patent.  
• Percent of total examples in the patent that are prophetic.  
• Whether the patent has some prophetic examples, as compared to 
patents that have no prophetic examples.  
• Whether the patent has only prophetic examples, as compared to 
patents that have either no prophetic examples or some prophetic 
examples.  
 
For convenience, this Article generally presents results using the first of these 
measures. However, each analysis was also conducted using the other 
measures, and the results were comparable. Where results are different, these 
differences are noted in the text.  
 
3. Selecting Industries 
 
Patents are drafted differently in different industries.197 This reflects both 
the varied nature of the technologies and differences in how the law is 
applied.198 In particular, the bar for enablement and written description are 
higher in industries such as chemistry and the life sciences as compared to the 
mechanical, electrical, or computer industries.199 Thus, there is reason to 
expect that examples (both prophetic and working) will be more common in 
chemistry and life sciences patents. To test this, I obtained industry 
classifications from NBER.200 As shown in Figure 1, examples are vastly more 
common in chemical and life sciences patents.  
 
                                                 
197 See generally, Dan L. Burk & Mark A. Lemley, Policy Levers in Patent Law, 89 VA. L. 
REV. 1575, (2003). 
198 Id. at 1576. 
199 Christopher A. Cotropia, The Folly of Early Filing, 61 HASTINGS L.J. 65, 74-75 (2009). 
200 NBER classifications are used here because they are simpler and fewer in number than 
IPC classifications. IPC classifications are used for the remainder of the Article because NBER 
classifications are only current through 2015 and because NBER does not classify applications. 
 
FIGURE 1: Percentage of Patents with a Separate Examples Section, 
by Industry (patents issued Jan 1976-May 2017) 
 
Note that the paucity of examples outside of the chemical and life sciences 
is not because information conveyed through examples are is not present in 
patents from those fields. Rather, it is attributable to drafting differences. 
Mechanical, electrical and computer patents frequently contain descriptions of 
embodiments – and these are frequently prophetic – but by convention drafters 
in these industries do not put embodiments into a specific examples section. 
Thus, the graph above should be interpreted not as indicating that examples are 
infrequent in some industries, but instead as indicating that this Article’s 
methodology works better for chemical and pharmaceutical patents. 
 
Because this Article’s methodology works better for chemical and 
pharmaceutical patents, the remainder of this Article studies only these 
industries. All experiments and graphs below represent an analysis of only 
chemical and pharmaceutical patents. 
 
Outside of Figure 1, the population analyzed is all US chemistry and 
biology patents and applications available electronically from the USPTO. 
Chemistry patents are identified as those belonging to IPC classes beginning 
with the code “C” (a category defined as “Chemistry; Metallurgy”).201 Biology 
patents are identified as those belonging to IPC classes beginning with the 
codes A61 and A62 (categories defined as “Medical or Veterinary Science; 
Hygiene” and “Life-Saving; Fire-Fighting”, respectively).202  
 
                                                 
201 World Intellectual Property Organization, International Patent Classification Scheme 
http://web2.wipo.int/classifications/ipc/ipcpub?notion=scheme&version=20170101&symbol=
none&menulang=en&lang=en&viewmode=m&fipcpc=no&showdeleted=yes&indexes=no&he
adings=yes&notes=yes&direction=o2n&initial=A&cwid=none&tree=no&searchmode=smart 
202 Id. 
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B.  The Prevalence of Prophetic Examples 
 
Having determined that only certain industries use prophetic examples in a 
format easily measured by this methodology, this Section studies a population 
comprised of all chemistry and biology patents and applications. This Section 
reports the prevalence of prophetic examples. If prophetic examples are rare, 
perhaps we need not be concerned about their existence even if they are 
theoretically problematic. If prophetic examples are common, the task of 
weighing their justifications, harms, and benefits is more urgent.  
 
As shown in Table 1, prophetic examples are indeed prevalent. Table 1 
summarizes the use of examples, both working and prophetic in patents. 
Approximately half of all chemistry and biology patents contain examples. Of 
the patents with examples, close to a quarter contain some prophetic examples, 
and about six percent contain only prophetic examples. The studied population 
contains over one million prophetic examples in total. 
 
Table 1: Prevalence of Working and Prophetic Examples 
 
Although prophetic examples are prevalent, their use is decreasing over 
time. For patents with a priority date of 1981, when prophetic examples were 
first explicitly allowed by the Patent Office, 26% of examples were prophetic 
and 9.6% of patents contained only prophetic examples. By 2015, this had 
dropped to 9% and 4%. Figure 3, below, shows the average number of 
prophetic examples per patent in each year. This average decreases from 2.02 
                                                 
* Percent of the number of patents with examples. 
204 Utility patents only; design patents and plant patents were excluded. 
205 Utility applications only; design applications and plant applications were excluded. 
 Patents in 
population 
Patents in 
population 
with 
examples 
Working 
examples, 
number 
(percent) 
Prophetic 
examples, 
number 
(percent) 
Patents 
with no 
prophetic 
examples, 
number203 
(percent*) 
Patents 
with some 
(but not all) 
prophetic 
examples, 
number 
(percent*) 
Patents 
with all 
prophetic 
examples, 
number 
(percent*) 
Chemistry 
and biology 
patents 
(1976-
2017)204 
1,160,471 559,406  
5,063,847 
(83%) 
1,049,042 
(17%) 
391,839 
(70%) 
131,871 
(24%) 
35,696 
(6%) 
Chemistry 
and biology 
applications 
(2001-
2017)205 
1,054,087 463,743 
5,222,946 
(84%) 
964,321 
(16%) 
271,820 
(59%) 
177,996 
(38%) 
13,926 
(3%) 
 
in patents with a priority date in 1981 to 1.12 in patents with a priority date in 
2015. 
 
Figure 2: Number of Prophetic Examples Per Patent Over Time (Granted 
Biology and Chemistry Patents with Examples, N=559,406) 
 
The reason for this decrease is not clear. It may be that as patents have 
become more expensive to file, there is less appetite for spending attorney time 
on drafting prophetic examples. It may also be that the behavior of particular 
patentees has not changed, but the type of entity filing patents has changed. For 
example, in the pharmaceutical industry, large companies have been filing 
fewer patents and relying more on research done – and patents filed – by small 
companies and universities. As discussed further in Section D(2), small 
companies file fewer prophetic examples so, if they make up an increasing 
share of pharmaceutical patentees, the average number of prophetic examples 
per patent will decrease. As shown in Appendix 5, the use of prophetic 
examples by large and small pharmaceutical patentees has stayed relatively 
steady over time, but small entities file a greater percentage of all 
pharmaceutical patents over time.  
 
Overall, there are likely many reasons for the decrease in the number of 
prophetic examples over time, and the dynamics surrounding the use of 
prophetic examples are likely complex. Note that the percent of patents with at 
least one prophetic example has not changed over time.206 
                                                 
206 Results not reported here.  Results will be reported in an online appendix if possible. 
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C.  Testing the Costs and Benefits of Prophetic Examples 
 
1. Do Prophetic Examples Help Patentees? 
 
At its most basic, the argument for prophetic examples is that they help 
patentees, and by doing so incentivize innovation and benefit society more 
broadly. I begin by looking at the correlation between prophetic examples and 
several general value indicators. These do not address any specific mechanisms 
by which prophetic examples may affect patent value, but provides descriptive 
information about the overall relationship between prophetic examples and 
patent value.  
 
I then address the specific mechanisms by which prophetic examples 
should add value: breadth and early-filing. I also analyze use of prophetic 
examples in the specific situations in which prophetic examples should be 
especially helpful: when the inventor is a small company, when human 
experiments are necessary, and when the experiments are very expensive. 
 
a. Value 
 
There is no perfect measure of patent value,207 but one commonly used 
indicator is the maintenance rate.208 The Patent Office requires that patentees 
pay maintenance fees at 3.5, 7.5, and 11.5 years after grant. These fees are 
substantial enough ($1,600, $3,600, and $7,400, respectively) that many 
patentees do not pay them, which results in the abandonment of the patent.209 
Maintenance is a proxy for value because a patent owner that pays the 
maintenance fee presumably values the patent at some amount higher than the 
cost of the fee. 
 
Figure 3 shows the correlation between number of examples – both 
prophetic and working – and payment of the year 11.5 maintenance fee.210 For 
each additional prophetic example in a patent, the likelihood that the 
                                                 
207 It is also not possible to empirically study every known facet of patent value. For 
example, many patents may be valuable as signaling tools or negotiation pieces. See, e.g., 
Michael J. Burstein, Exchanging Information Without Intellectual Property, 91 TEX. L. REV. 
227, 241 (2012) (describing – and questioning – the premise that intellectual property is 
necessary for information exchange). 
208 E.g., James Bessen, The Value of US Patents by Owner and Patent Characteristics, 37 
RES. POL’Y 932, 932 (2008); Jean O. Lanjouw et al., How to Count Patents and Value 
Intellectual Property, 46 J. INDUS. ECON. 405, 406 (1998). 
209 United States Patent and Trademark Office, USPTO Fee Schedule (Sept. 1, 2017), 
available at, https://www.uspto.gov/learning-and-resources/fees-and-payment/uspto-fee-
schedule#Patent Maintenance Fee. The fees are halved for small entities and reduced further 
for micro entities. 
210 Figure 3 shows the correlation between examples and the last maintenance fee, 
however, results for payment of other maintenance fees are similar. 
 
maintenance fee will be paid decreases. By contrast, the directionality of the 
correlation is opposite for working examples. Figure 3 does not include 
controls, however, the correlation remains when controlling for priority year, 
industry, and other factors. A regression with controls can be found in 
Appendix 3. Patents with more prophetic examples are less likely to pay 
maintenance fees, and thus may be less valuable. 
 
 
Figure 3: Relationship Between Number of Examples and Payment of 
Maintenance Fees (Granted Biology and Chemistry Patents with Examples, 
1981-2005, N=305,650) 
 
A second proxy for patent value is the number of forward citations.211 If a 
patent covers an important technology, others will be more likely to cite it. The 
correlation between the number of prophetic examples and forward citations 
per year (controlling for issue year) is reported in Appendix 3. As the number 
of prophetic examples increases, the rate of forward citations decreases. This 
again indicates that patents with more prophetic examples may be less 
valuable. 
 
Another common method of determining if a particular characteristic 
correlates with patent value is to look at how frequently that characteristic 
                                                 
211 Bronwyn H. Hall et al., Market Value and Patent Citations, 36 RAND J. ECON. 16, 17 
(2005). Note that forward citations are a messy and imprecise measure of patent value. C. Gay 
& C. Le Bas, Uses Without Too Many Abuses of Patent Citations or the Simple Economics of 
Patent Citations as a Measure of Value and Flows of Knowledge, 14 ECON. INNOVATION & 
NEW TECH. 333, 335 (2005). 
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appears in a specific group of patents that is known to be valuable.212 Often 
this group of “valuable patents” consists of litigated patents, because litigated 
patents are valuable enough to be worth challenging and defending in court.213 
Appendix 3 shows the correlation between likelihood of litigation and 
prophetic examples. Patents with a small number of prophetic examples show 
little difference in litigation rates as compared to patents with no prophetic 
examples. However, patents with many prophetic examples are considerably 
less likely to be litigated.214 As with the measures above, this suggests that 
patents with many prophetic examples are less valuable than patents with no 
prophetic examples. 
 
In the context of biology and chemistry patents, there is a second group of 
“valuable patents”: Orange Book-listed patents. The Orange Book is a 
publication maintained by the Food and Drug Administration which lists 
patents covering approved drug products.215 It is expensive and time 
consuming to obtain approval for a drug product, so most patents listed in the 
Orange Book are extremely valuable.216 
 
Orange Book patents are also interesting because prophetic examples are 
thought to be particularly useful in pharmaceutical patents more generally. 
This is because these are the patents that are most likely to have human 
examples,217 the pharmaceutical sciences are fast moving,218 have a high bar 
for enablement and written description,219 and are often very valuable.220 Thus, 
we might particularly expect to see prophetic examples adding value in 
pharmaceutical patents. However, Orange Book patents are not a uniform 
group, and more study is needed to understand the uses of prophetic examples 
in different types of Orange Book patents,221 as well as to understand how 
                                                 
212 John R. Allison, Mark A. Lemley, Kimberly A. Moore, & R. Derek Trunkey, Valuable 
Patents, 92 GEO. L.J. 435 (2003). 
213 Id. 
214 One possibility is that the patent office has allowed invalid patents because it is not 
able to fully conduct the enablement and written description analysis, but patent owners do not 
believe that their patents would hold up in court and thus do not assert them. See Sean 
Seymore, Patent Asymmetries, 49 U.C. DAVIS L. REV. 963, 965 (2016).  
215 Food and Drug Administration, Orange Book Preface (Jan. 24, 2017), available at 
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm. Though widely 
known as the “Orange Book,” the publication is officially titled Approved Drug Products with 
Therapeutic Equivalence Evaluations. 
216 C.S. Hemphill & B.N. Sampat, Evergreening, Patent Challenges, and Effective Market 
Life of Pharmaceuticals, 31 J. HEALTH ECON. 327, 330 (2012). 
217 TOM BRODY, CLINICAL TRIALS, 837 (2016). 
218 ROBIN FELDMAN, RETHINKING PATENT LAW, 160 (2012). 
219 Dan L. Burk & Mark A. Lemley, Is Patent Law Technology-Specific, 17 BERKELEY 
TECH. L.J. 1155, 1183 (2002). 
220 Hemphill & Sampat, supra note 216, at 328. 
221 Patents may cover, for example, the active ingredient in the drug (drug substance), the 
formulation or composition of the drug (drug product), or a method of using the drug. These 
are often drafted at different points in the drug lifecycle, and may have very different strengths 
and weaknesses. See Janet Freilich, The Paradox of Legal Equivalents and Scientific 
 
prophetic examples relate to various types of strategic behavior that has been 
documented in relation to Orange Book listing.222 
 
Appendix 3 shows the correlation between likelihood of Orange Book 
listing and prophetic examples. Unlike the value measure seen before, use of 
prophetic examples does correlate with value by this measure. Orange Book 
listed patents are considerably more likely to include prophetic examples as 
compared to patents that are not Orange Book listed.  
 
Orange Book listed patents are quite different from most patents – they 
cover a very specific type of technology, are filed by a small set of companies, 
and are often the product of extensive investment. They are also a very small 
group – the FDA estimates that it listed 602 unique patents in 2014.223 Thus, 
Orange Book listed patents suggest that prophetic examples can be valuable in 
that specific group, but the results are unlikely to be applicable to the broader 
patent population. 
 
Yet another proxy for value is grant rate; the likelihood that the PTO will 
grant a patent. Appendix 4 shows that – unlike most of the measures seen 
above – applications with more prophetic examples are somewhat more likely 
to be granted than applications with fewer prophetic examples.224 
 
b. Breadth 
 
Prophetic examples are predicted not only to add value generally, but to do 
so in several specific ways. One of these is that prophetic examples allow 
patentees to obtain broader patents than they otherwise could have done. Here, 
I test this claim using a proxy for patent scope: the number of words in the 
shortest independent claim of the patent.225 The mechanism behind this proxy 
                                                                                                                                
Equivalence, 66 S.M.U. L. REV. 59, 84-87 (2013). 
222 For example, merely listing a patent in the Orange Book is valuable for the patentee, 
even if the validity of the patent does not hold up in court. For an overview of such strategic 
behavior, see e.g., Natalie Derzko, The Impact of Recent Reforms of the Hatch-Waxman 
Scheme on Orange Book Strategic Behavior and Pharmaceutical Innovation, 45 IDEA 165 
(2005). 
223 81 Fed. Reg. 54097 (Aug. 15, 2016). For comparison, the PTO granted 326,032 patents 
in 2014. United States Patent and Trademark Office Patent Technology Monitoring Team, U.S. 
Patent Statistics Chart Calendar Years 1963-2015, available at 
https://www.uspto.gov/web/offices/ac/ido/oeip/taf/us_stat.htm. 
224 This measure does not include continuations or unpublished applications. For a 
discussion on the challenges of measuring allowance rate see Michael Carley, Deepak Hedge, 
& Alan Marco, What is the Probability of Receiving a U.S. Patent?, 17 YALE J.L. & TECH. 
203, 206 (2015). 
225 Jeffrey M. Kuhn & Neil Thompson, The Ways We’ve Been Measuring Patent Scope 
are Wrong: How to Measure and Draw Causal Inferences with Patent Scope, (May 2017), 
available at https://ssrn.com/abstract=2977273; Alan C. Marco, Joshua D. Sarnoff, & Charles 
deGrazia, Patent Claims and Patent Scope, USPTO Economic Working Paper 2016-04 
(October 2016), available at https://ssrn.com/abstract-2844964. 
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is that additional words in a claim add additional restrictions, thereby 
narrowing the claim (for example, the set of objects in the category “sofas” is 
broader than the set of objects in the category “blue sofas”). I applied this 
proxy to the dataset of this Article in order to determine whether use of 
prophetic examples correlated with increased breadth. 
 
Figure 4 shows the correlation between the number of examples and the 
average number of words in independent claims. As the number of prophetic 
examples in a patent increases, the average number of words in the patent’s 
independent claims also increases – meaning that the scope of the patent is 
narrower. By contrast, the number of working examples is negatively 
correlated with the scope proxy, meaning that as the number of working 
examples in a patent increases, the patent is broader. Figure 4 does not include 
controls, however, the correlation remains when controlling for priority year, 
industry, and other factors.226  
 
Figure 4: Correlation Between Number of Examples and Patent Breadth 
(Granted Chemistry and Biology Patents with Examples, 1976-2016; 
N=559,404) 
 
                                                 
226 See Appendix 3. 
 
c. Early Filing 
 
Prophetic examples should allow patentees to file a patent application 
earlier than would be possible in the absence of prophetic examples.227 It is not 
possible to measure whether a patent with prophetic examples was filed earlier 
than it otherwise would have been, since the counterfactual is not observable. 
However, we can observe situations in which patentees were rushing to file 
applications at the patent office; situations in which they might be expected to 
use prophetic examples to file quickly. One such situation occurred around the 
effective date of the America Invents Act (“AIA”). 
 
The AIA was a major overhaul of several elements of the U.S. patent 
system. These changes were to some extent unfavorable to patentees, and thus 
patentees rushed to file applications before the effective date of these 
measures: March 16, 2013.228 Patents filed before March 16, 2013 were subject 
to pre-AIA rules. Figure 5, below, shows the number of patent applications 
filed each day in the month before and after March 16, 2013. The enormous 
spike in applications filed in the days before the AIA came into effect is 
evidence of patentees’ rush to the patent office. This rush is also confirmed by 
numerous contemporary accounts.229 
 
Figure 5: Daily Patent Applications Filed Between Feb. and June 2013 
(Biology and Chemistry Applications with Examples, N=24,554) 
Patentees rushing to file an application with the Patent Office would have 
faced a choice: conduct time-consuming experiments that might not be 
finished by March 16, 2013, or file an application with prophetic examples. If 
prophetic examples are used to aid early-filing, we would expect to see an 
                                                 
227 Section II.A.1, supra. 
228 Different provisions of the AIA had different effective dates. 
229 Dennis Crouch, Pre-AIA Filing Number, PATENTLY-O (March 29, 2013), available at 
https://patentlyo.com/patent/2013/03/pre-aia-filing-numbers.html 
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increase in the use of prophetic examples in the days and weeks before the 
effective date of the AIA, followed by a return to previous rates after the 
effective date of the AIA. 
 
Surprisingly, the number of prophetic examples used in patents filed right 
before March 16, 2013 is essentially the same as the number of prophetic 
examples used in patents filed after March 16, 2013 (see Figure 6). There is no 
evidence that patentees were using prophetic examples to rush applications to 
the Patent Office. 
 
Figure 6: Mean Daily Prophetic Examples in Patent Applications Filed 
Between Feb. and June 2013 (Biology and Chemistry Applications with 
Examples, N=24,554) 
 
* * * 
 
In sum, prophetic examples are negatively correlated with most value 
measures. Further, there is no evidence that use of prophetic examples leads to 
broader or earlier-filed patents. Although prophetic examples do correlate with 
Orange Book listings, this is unlikely to indicate a broadly applicable benefit of 
such examples. Mechanisms for and implications of these findings are 
discussed further in Section IV.  
 
d. Small Entities 
 
Proponents of prophetic examples argue that they are an equalizer between 
large companies, who have the resources to conduct extensive experiments, 
and small companies, who lack extensive resources.230 This Section tests how 
frequently prophetic examples are used by small companies. 
 
                                                 
230See Aisenberg, supra note 101, at 30. 
 
The Patent Office classifies patent applications based on whether they were 
filed by large entities or small entities (a category that includes individuals, 
small business, nonprofits, and universities).231 Figure 7(a) shows that use of 
prophetic examples is negatively correlated with small entity status; small 
entities use fewer prophetic examples.  
 
Figure 7(b) shows the total number of prophetic examples in granted 
patents filed by small entities as compared to large entities. Small entities have 
filed a total of 92,117 prophetic examples, while large entities have filed a total 
of 611,842 prophetic examples. Thus, small entities account for only 13% of 
all prophetic examples. Even if prophetic examples are justifiable on the 
grounds that they are necessary for small companies, that explanation cannot 
justify 87% of prophetic examples. Further, it is unlikely that prophetic 
examples are necessary for most small companies, as 70% of patents filed by 
small entities contain no prophetic examples. However, small entities are 
somewhat more likely to use small numbers (one to three) of prophetic 
examples as compared to large entities.232 This suggests that prophetic 
examples may have some particular usefulness for small entities and is an area 
that merits further study. 
 
Figure 7: Use of Prophetic Examples by Small Entities (Biology and 
Chemistry Granted Patents with Examples, 1981-2016, N=559,404) 
  
 7(a)    7(b)  
 
e. Human Data 
 
One justification for prophetic examples is that pharmaceutical companies 
                                                 
231 37 C.F.R. § 1.25. The Patent Office recently introduced a new category: micro entities. 
Because micro entity status first became available in 2013, and therefore is not relevant to the 
majority of the population studied here, I classify micro entities as small entities for purposes 
of this study.  
232 Appendix 3, infra. 
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cannot conduct real experiments because they cannot obtain data from human 
trials without FDA permission.233 I reviewed 1,000 prophetic examples 
selected randomly from the population of biology and chemistry patents issued 
from 1976 to 2017 to determine if the examples involved human data. 
 
As can be seen from Table 3, below, human experiments account for only 
1.9% of prophetic examples. This suggests that very few prophetic examples 
are used to get around the problem of filing patents before FDA approval for 
human studies. Note that although Orange Book listed patents are all related to 
drugs to treat humans, only 6% of prophetic examples in those patents describe 
human studies.234 Therefore use of human studies does not explain most of the 
use of prophetic examples in Orange Book listed patents. 
 
Even if human experiments are a justifiable use of prophetic examples, this 
specific use is rare and cannot justify the vast majority of prophetic examples. 
 
f. Expensive Experiments 
 
Another justification for prophetic examples is in instances where 
experiments would be extremely time-consuming or expensive. It is difficult to 
know whether an experiment is time-consuming or expensive. As a proxy, I 
reviewed the same 1,000 prophetic examples to determine if they contained 
experiments on animals. Animal studies are more expensive and time 
consuming than studies in cells which are in turn generally more expensive and 
time consuming than studies of molecules or chemicals in test tubes (in vitro 
studies), and thus are a rough alternative for data on the actual time and 
expense of experiments. 
 
Table 3 provides at least partial evidence that many prophetic examples are 
based on relatively inexpensive experiments. Most prophetic examples are in 
vitro experiments. While such experiments can still be expensive, they are less 
expensive than in vivo experiments. Thus, expense of conducting real 
experiments may not be a full explanation for use of prophetic examples. 
However, I use a very rough proxy for expense here, so further study is 
                                                 
233 Section II.A.2, supra. 
234 6% of a sample of 100 prophetic examples selected randomly from biology and 
chemistry patents issued between 1976 and June 2017 and listed in the Orange Book as of 
August 2017. 
Table 3: Percent of prophetic examples that describe in vitro, cell, animal, 
or human studies; N=1,000 
Type of Experiment Prophetic Examples 
Human 1.9% 
Animal 3.1% 
Cell 3.6% 
In vitro 91.4% 
 
necessary. 
 
2. Are Prophetic Examples Inaccurate or Misleading? 
 
The prior section asked whether prophetic examples are beneficial because 
they help patentees and concluded that there is little evidence of such a benefit. 
This section asks whether prophetic examples are harmful. As set out in Part II, 
such harm may arise if prophetic examples are inaccurate or mislead scientists. 
 
a. Role of the Examiner 
 
If patent examiners police the accuracy of prophetic examples by rejecting 
examples that seem utterly implausible, we might have some confidence that 
the remaining examples are likely to be accurate. Examiners have the power to 
do this. They can reject a patent claim if it describes an invention that is simply 
too incredible to be believable235 and can request that the applicant submit 
more evidence.236 However, there is reason to doubt that examiners make such 
rejections. The Patent Office emphasizes that these rejections are “rare,” 
instances where such a rejection was upheld by a federal court “even rarer,” 
and that requests for additional evidence “should be imposed rarely.”237 The 
Patent Office allows examiners to make the rejection only if the assertion is 
“incredible in view of contemporary knowledge” and not merely where “there 
may be reason to believe that the assertion is not entirely accurate.”238  
 
To test how often patent examiners rejected patent claims because of 
prophetic examples or otherwise mentioned prophetic examples, I read the 
prosecution histories of 100 randomly selected patents that contained only 
prophetic examples. These patents had all been rejected for lack of enablement 
or utility, which is where mention of a prophetic example would be most likely 
to occur. None of the prosecution histories ever mentioned prophetic examples. 
This result suggests that examiners are generally accepting of prophetic 
examples and do not often request corroborating data. 
 
This result is consistent with the high grant rate for patents with prophetic 
examples.239 All evidence suggests that examiners treat prophetic examples 
just as they do working examples. This may reduce the overall accuracy of 
prophetic examples because even those that seem incredible – such as the one 
cited in the introduction of this Article – pass through prosecution without 
                                                 
235 MPEP § 2107. 
236 Id. Although this rejection is allowed in the context of the utility requirement, it has the 
potential to allow examiners to express skepticism of prophetic examples and request 
corroborating data to bolster the prophecy. 
237 Id. 
238 Indeed, examiners reject applications for lack of credible utility mainly when the 
claimed invention “violated a scientific principle, such as the second law of thermodynamics.” 
Id. 
239 Section III.D.1.a, supra. 
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objection. 
 
b. How Prophetic Examples are Cited 
 
To directly test whether prophetic examples are misleading scientists, I 
observed how prophetic examples were cited in the scientific literature. If a 
document citing to a prophetic example states, either explicitly or implicitly, 
that the example is hypothetical, then the citing document is correctly 
interpreting the example. If the citing document refers to the prophetic 
example as if the example were factual, then the citing document is incorrectly 
interpreting the example.  
 
I used a random sample of 100 patents that are cited by scientific articles. 
All patents in the sample contain only prophetic examples and no working 
examples. Citations do not always indicate the specific part of the patent to 
which a citation refers, therefore if a patent has both prophetic and non-
prophetic information, it is often impossible to know which information is 
cited. Patents with only prophetic examples do not have this limitation: if a 
document cites to such a patent, the document must be citing prophetic 
information. 
 
I used Google Scholar to search for non-patent references citing each 
patent in the sample. I selected the first listed reference that cited the patent 
substantively for a specific proposition. If a patent was not cited substantively 
in Google Scholar, I excluded that patent and replaced it with another 
randomly selected patent in my sample.240 I then determined whether it was 
clear from the citing document that the cited information was prophetic, or 
whether the citing document cited the prophetic example as if it were factual. 
 
Strikingly, of the 100 studied patents, 99 were not cited in a manner that 
made it clear that the cited information was prophetic. This strongly suggests 
that prophetic examples are misleading to scientists. The article that cited a 
prophetic example correctly was written by a scientist who is himself listed as 
an inventor on 34 patents and applications, suggesting that he has more 
experience with the patent system than most.241 
 
                                                 
240 Most patents are not cited by non-patent literature.  I reviewed 912 patents to obtain the 
sample of 100 cited patents used here. 
241 The author is Mark R. Prausnitz, a professor at the Georgia Institute of Technology. 
See Mark R. Prausnitz, Laboratory for Drug Delivery, http://drugdelivery.chbe.gatech.edu/.  
 
 
c. Use of Results 
 
As a further test of whether prophetic examples are inaccurate or whether 
readers are likely to be misled, I observed whether prophetic examples 
consisted just of protocols, or whether they also included experimental results.  
 
For instance, a prophetic example might say “formulation J [a drug 
compound] is be administered once daily topically to the eye of a person 
suffering from glaucoma” – which is simply an experimental protocol.247 
Alternatively, the prophetic example might continue with results: “[a]fter a few 
hours, intraocular pressure drops more and less hyperemia [eye redness] is 
observed than would be observed for formulation A.”248  
 
If prophetic examples include results, particularly detailed results, it is an 
indicator of both inaccuracy and the likelihood that readers will be misled. For 
accuracy: the more results that are included in the example – and the more 
detailed the results – the less likely the example is to be accurate.249 To use the 
                                                 
242 Samples are all excerpts from scientific journal articles. 
243 Emphasis added. M. Suresh et al., Metal Organic Framework MIL-101(Cr) for 
Dehydration Reactions, 126 J. CHEM. SCI. 527, 527 (2014). 
244 Emphasis added. Heon-Gon Kim et al., Synthesis of Heteroaryl Substituted Imidazole 
Derivatives, 21 BULL. KOREAN CHEM. SOC. 345, 345 (2000). 
245 Emphasis added. DANIEL BLANCO ANIA, PARALLEL SYNTHESIS OF POTENTIAL DRUGS 
BASED ON THE 2-ARYLETHYL AMINE MOIETY, 10 (2009). 
246 Mark R. Prausnitz, Microneedles for Transdermal Drug Delivery, 56 ADVANCED DRUG 
DELIVERY REVIEWS 581, 581 (2004). 
247 U.S. Patent No. 8,278,353, Example 5. 
248 Id. The results were included in the example, and the use of the prophetic example to 
show written description was upheld by the Federal Circuit in Allergan, Inc. v. Sandoz, Inc., 
796 F. 3d 1293, 1303, 1309 (Fed. Cir. 2015). 
249 Prophetic results and data should be “included in patent applications only where the 
inventor has a very high level of confidence in their operability.” ROBERT D. FIER, CHEMICAL 
PATENT PRACTICE 44 (1975). 
Table 5: Miscitation of Prophetic Examples (%); N=100 
 Prophetic 
Examples 
Samples to illustrate categories242 
Cited 
Incorrectly 
99% 
“Dehydration reaction in gas phase has been carried out over solid acid catalysts…”243 
 
“Useful synthesis methods of imidazole derivatives were known to include several 
intermediates such as…1,2-diketones…”244 
 
“Hydroxyimination of aromatic ketones, followed by reduction, was used by Cannon et 
al. [in a prophetic example] to synthesize conformationally restricted derivatives of 
dopamine….”245 
Cited 
Correctly 
1% 
“Although the microneedle concept was proposed in the 1970s [in prophetic examples] it 
was not demonstrated experimentally until the 1990s....”246 
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example above, it is surely easier to predict that formulation J will treat 
glaucoma250 than to predict that it will work better than formulation A and that 
the effects will occur after just a few hours. 
 
For likelihood of misleading readers: including results in prophetic 
examples– and particularly detailed numerical results – is one of the easiest 
ways to confuse the reader.251 We do not usually write results for experiments 
that we have not conducted. Patent readers are therefore conditioned to view 
any results in experiments as the product of actual experimentation, rather than 
prophesy.  
 
Thus, whether or not a prophetic example contains results is an indication 
of whether that example is both inaccurate and misleading. In order to test 
whether prophetic examples contained results, I reviewed 1000 prophetic 
examples selected randomly from the population of biology and chemistry 
patents issued from 1976 to 2017. I classified each example in one of the three 
following categories: 
• No results. These examples typically described protocols or listed 
ingredients without any information about the outcomes or final product. 
• Some results. These examples included general information about the 
results of the experiment, but did not describe specific numerical results. 
Often these examples simply reported that the experiment worked and 
produced the desired result. The examples sometimes include adjectives 
characterizing the results in a nebulous manner. 
• Detailed results. These examples included results with some detailed 
description of the results. This was generally numeric results. 
 
Table 4 shows the percent of prophetic examples in each of the three 
categories and samples to illustrate the contents of each category. A majority 
of prophetic examples contain at least some results, which suggests that 
prophetic examples may frequently be inaccurate and misleading. 
  
                                                 
250 In fact, formulation J does treat glaucoma. The patent protects the drug Lumigan®, 
which is approved by the FDA for treatment of glaucoma. 
251 SUTTON, supra note 194, at § 9.17 (explaining that may be misleading if they 
“conclude with a statement describing the results that were obtained…where in fact no results 
have actually been obtained.”). Sutton cautions that “as a general rule, no results should be 
described unless they have actually been achieved.” Id. Another guide recommended that 
prophetic results and data should be “included in patent applications only where the inventor 
has a very high level of confidence in their operability.” FIER, supra note 249, at 44 (1975). 
 
 
 
IV. DISCUSSION, IMPLICATIONS, AND REFORM 
 
In this Section, I apply the empirical findings of Section III to the costs and 
benefits of prophetic examples set out in Section II. I argue that the costs of 
prophetic examples are high and the benefits hard to determine, so I conclude 
with suggestions for reform. 
 
A.  Do Prophetic Examples Help Patentees? 
 
The core argument for prophetic examples is that they are valuable to 
patentees, and that value to patentees translates into value to society.256 
However, it is far from clear that prophetic examples actually help patentees. 
First, the number of prophetic examples in a patent correlates negatively with 
most proxies for patent value: maintenance, forward citations, and litigation 
                                                 
252 Samples are all excerpts from prophetic examples. 
253 U.S. Patent No. 6,837,925, Example 8 (issued Jan. 4, 2005). 
254 U.S. Patent No. 8,313,739, Example 31 (issued Nov. 20, 2012). 
255 U.S. Patent No. 9,453,125, Example 2 (issued Sept. 27, 2016). 
256 Section II.A, supra. 
Table 4: Prophetic Examples That Include Results (%); N=1,000 
 Prophetic 
Examples 
Samples to illustrate categories252 
No 
results 
42% 
“A solution of [several compounds] is dissolved in DMF (50 mL). The reaction mixture 
is stirred under nitrogen and at room temperature for 18 h. The solvents are removed in 
vacuo and the crude material is triturated in ethyl acetate, filtered and washed with ethyl 
acetate. The crude product thus obtained is dissolved in 50 mL of 50% TFA/DCM and 
the reaction mixture is stirred for 3 h at room temperature under nitrogen.”253 
Some 
results 
17% 
“Mice are then treated with the test article or associated vehicle by intraperitoneal 
injection of 0.1 ml of the indicated solution. Mice in the first group (n=24) are treated 
with vehicle…which is injected on day 0, 2, 4, 5, and 8…All the mice are sacrificed on 
day 18, and lungs are collected for quantitation of tumor…In both groups of mice 
created with zctyo24 or zcyto25, the average number of tumor foci present on lungs is 
significantly reduced compared to mice treated with vehicle.”254 
Detailed 
results 
41% 
“Styrene monomer is polymerized in the presence of the rubber under dynamic 
conditions for controlling the rubber particle size, after phase inversion, as the 
polymerization proceeds…The composition and properties of Example 2 are shown in 
Table 1 and Table 2 below. The flexural modulus of Example 2 is increased by about 
10% or more (e.g., about 15% or more) compared with Example 1. The tensile modulus 
of Example 2 is increased by about 10% of more (e.g., about 15% or more) compared 
with Example 1. Despite having a generally high concentration of monovinyl aromatic 
polymer and a generally low concentration of elastomeric polymer, Example 2 has 
improved resistance to environmental stress cracking compared with Example 1…”255 
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rates.257 Similarly, although patenting guides recommend use of prophetic 
examples to obtain a broader patent, use of prophetic examples is negatively 
correlated with patent breadth.258 Further, there is no evidence that patentees 
use prophetic examples to file early.259  
 
Nevertheless, there are a few indications that prophetic examples add 
value. First, patentees must believe that prophetic examples are useful and 
increase patent value in some way; otherwise they would not use prophetic 
examples. Second, prophetic examples appear more frequently in Orange Book 
listed patents, although these are a small group of atypical patents, so 
information drawn from these patents may not be generalizable.260 Third, 
applications with more prophetic examples are more likely to be granted by the 
Patent Office, suggesting that prophetic examples may add value during 
prosecution.261 
 
Overall, the results above demonstrate a surprisingly ambiguous – and 
probably negative – correlation between use of prophetic examples and patent 
value. However, the empirical analysis does not reveal the mechanism driving 
this correlation. I suggest such a mechanism below. 
 
1. Proposed Mechanisms 
 
A possible mechanism to explain the results is that prophetic examples are 
useful mainly in low-value patents. Under this mechanism, adding a prophetic 
example to a patent would increase the value of that patent as compared to the 
value of the same patent without the prophetic example. However, patentees 
would only choose to add prophetic examples in situations where they were 
necessary, such as instances where the patentee had no working examples or 
where the patentee was in a hurry to file the application. These situations might 
be those where the patent is inherently weaker. 
 
There are many explanations for why patentees with no or little real data 
might have weaker patents. A patentee might be filing a patent on a mere 
guess; and that guess may turn out to be wrong, rendering the patent less 
valuable. A company might file patents with prophetic examples in areas that 
are not top priorities for the company, and to which the company does not want 
to dedicate research dollars. Since the area was not a priority, the company 
may then choose not to pursue research in that direction and abandon the 
patent. A patentee may file a patent on a technology that she does not have 
funding to develop. She may then never obtain the funding and abandon the 
patent.  
                                                 
257 Section III.D.1.a, supra. 
258 Section III.D.1.b, supra. 
259 Section III.D.1.c, supra. 
260 Section III.D.1.a, supra. 
261 Id. 
 
 
Note that the patent’s weakness in these scenarios is not caused by the 
prophetic examples themselves; rather, situations in which prophetic examples 
are needed might be situations in which patents are weak.  
 
If prophetic examples are used mainly in weaker patents, why are they 
positively correlated with patent application grant rates? This may be 
explained by the difference in the meaning of value at the examination stage 
and value after this stage. Since examiners appear to treat prophetic examples 
as equal to working examples, prophetic examples may be very valuable 
indeed during examination. As theorized, they may help applicants obtain 
patents when the applicant cannot conduct real experiments. 
 
However, the real world may not view prophetic examples as kindly as 
examiners. Take, for instance, a patentee who recently obtained a patent by 
grace of prophetic examples. He seeks to partner with an established company 
to commercialize a product. The prospective partner will ask him for evidence 
that his invention works. He can produce only prophetic examples – which are 
unlikely to convince investors. Alternatively, a similar patentee may, after 
obtaining a patent, seek to build her product. She may discover that her 
prophesies are wrong and that her product does not work. The prophecies were 
enough for her to get a patent, but not enough to provide value past that stage. 
 
2. Implications 
 
a. Prophetic Examples May Encourage Weaker Patents 
 
If prophetic examples add value to individual patents, but are generally 
used to enable weaker patents, they may be a net loss for society. The patent 
literature is replete with criticisms of weak patents.262 Weak patents are a waste 
of money for both the applicant and the PTO. Weak patents increase 
transaction costs for other researchers.263 Weak patents chill research in 
surrounding areas.264  
 
If prophetic examples lead to patents that are weak and abandoned at 
                                                 
262 See, e.g., John R. Allison, Mark A. Lemley & Joshua Walker, Patent Quality and 
Settlement Among Repeat Patent Litigants, 99 GEO. L.J. 677 (2011); James Bessen & Michael 
J. Meurer, Lessons for Patent Policy from Empirical Research on Patent Litigation, 9 LEWIS & 
CLARK L. REV. 1, 2 (2005); Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter 
Innovation? The Anticommons in Biomedical Research, 280 SCI. 698, 698 (1998); Mark A. 
Lemley & Carl Shapiro, Patent Holdup and Royalty Stacking, 85 TEX. L. REV. 1991, 1992 
(2007); But see Mark A. Lemley, Ignoring Patents, 2008 MICH. ST. L. REV. 19, 21 (arguing 
that weak patents are often simply ignored). 
263 Robert Merges, Intellectual Property Rights and Bargaining Breakdown: The Case of 
Blocking Patents, 62 TENN. L. REV. 75, 90 (1994). 
264 Carl Shapiro, Navigating the Patent Thicket, 1 INNOVATION POLICY & ECON. 119, 122 
(2000). 
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higher rates, the patent itself may not be forcing others out of the area. 
However, even narrow and unenforceable patents can impede downstream 
research. This is both because downstream researchers may not know that the 
patent is narrow or unenforceable265 and because once an invention has been 
disclosed in one patent it becomes difficult for a later inventor to obtain a 
patent on a related invention.266 Awarding patents based on prophetic examples 
may prevent the use of exclusivity incentives for inventors who actually 
conduct the experiments. 
 
However, any criticism on these grounds is blunted by the number of 
prophetic examples in high value patents. In particular, some Orange Book 
listed patents are exceedingly valuable and cover novel pharmaceutical 
products that can be enormously beneficial.267 Outside of this small group, 
high value patents have fewer prophetic examples than low value patents, but 
high value patents nonetheless contain prophetic examples. It is very difficult 
to determine whether these patents could have been obtained in the absence of 
prophetic examples. This is because the enablement and written description 
standards are not bright line rules and there are many different ways to enable 
and adequately describe an invention. If prophetic examples encourage 
wastefully weak patents (and other harms, described below), is it worth 
permitting them if they add value to a smaller number of strong patents?  
 
b. Rationales for Early Filing Do Not Fit With Prophetic Examples 
 
There is a large literature on when patents should be filed and whether 
early filing is socially beneficial. Prophetic examples have surprising 
implications for this debate. Although proponents of early filing should favor 
prophetic examples, I argue that the use of prophetic examples as reported in 
this Article does not fit well with the benefits of early filing. The situations in 
which prophetic examples are most used may also be those situations in which 
early filing is the most problematic.  
 
For instance, early disclosure is used to justify early filing. But consider 
what exactly is disclosed in prophetic examples: fiction. Early disclosure of 
fictional data is presumably less beneficial than early disclosure of factual data. 
If prophetic examples were not permitted, patent applicants would file as early 
as possible after obtaining factual data, which would provide the earliest 
possible disclosure of that factual data.  
                                                 
265 It is difficult to know if a patent is valid, so even patents that are likely invalid can have 
chilling effects. See, e.g., Mark A. Lemley, Rational Ignorance at the Patent Office, 95 Nw. U. 
L. Rev. 1495, 1503 (2010).  
266 Section II.B.1, supra. 
267 Though others have faced accusations of “evergreening” – a practice of filing patents 
on variations of the original product that extends the life of the monopoly, but is not 
necessarily innovating or beneficial. See, e.g., Robin Feldman, Rethinking Rights in Biospace, 
79 S. CAL. L. REV. 1, 30 (2006). 
 
 
Moreover, prophetic examples describe the technical inner workings of the 
invention, rather than a broad concept. It may be beneficial for the public to 
obtain disclosure of a bright new idea earlier, in order for others to begin 
working on whatever secondary innovation the idea sparks. However, the 
utility of speculative disclosure of the inner workings of exactly how to make 
that idea functional – synthesis methods, for example, or precise doses, 
formulations, or dosage forms – is more dubious. First, it seems less likely to 
spark follow-on innovation. While the idea that compound X might be an 
antibiotic may lead to exciting new discoveries of related compounds that work 
in similar ways, or to other uses for compound X, these types of secondary 
innovation seem less likely to result from a prophetic example stating that, for 
example, compound X should be administered orally in doses of 2.5 mg. 
Second, the speculative disclosure of the inner workings of an invention is less 
likely to be accurate than speculative disclosure of a broad concept. This is 
simply because in order for the protocol to make or use the invention to be 
correct, the broad concept itself also has to be correct. Moreover, a broad 
concept may be wrong but may still have elements that could be useful, for 
example, Jules Verne could not make a submarine, but he could inspire others 
to pursue it. It seems less likely that a prophetic example describing, for 
example, a protocol for manufacturing pressure-resistant screws holding the 
walls of the submarine together, could be both wrong and yet so widely 
inspiring.  
 
Prospect theory is also used to justify early filing, and again, prophetic 
examples do not entirely fit with this justification. An adherent of prospect 
theory wants the patent to be granted early, but to someone equipped to 
develop the prospect. Prophetic examples allow patentees who have not done 
any experiments with a particular technology to obtain a patent on that 
technology over someone who has done experiments, because the prophetic 
patentee will be able to file first. However, a patentee who has done some 
experimentation may be in a far better position to develop his prospect. 
Further, the higher abandonment rate associated with patents with more 
prophetic examples suggests that many users of prophetic examples are not 
developing their prospects. 
 
The practical reasons for early filing – that patents are needed to obtain 
funding, or are needed to protect a company who must disclose the invention 
in order to contract with manufacturers and the like – may be valid even for 
prophetic examples. However, surely we can craft doctrine that addresses these 
practical concerns in a more targeted way that creates fewer problems. 
 
c. Why Aren’t All Examples Prophetic? 
 
In the context of constructive reduction to practice, scholars have expressed 
concerns that making patents available to inventors who have not physically 
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created their invention reduces the incentive to actually build and test the 
invention.268 The same argument applies to prophetic examples: if prophetic 
examples are available, is there any incentive to conduct real experiments?  
 
Apparently there is. Only 17% of examples in patents are prophetic. Given 
the clear advantages of prophetic examples,269 it is surprising that more 
patentees do not use them. The data on prophetic examples suggests that there 
may actually be significant incentives to physically reduce an invention to 
practice. This is surprising both in the context of prophetic examples and in the 
larger literature on the doctrine of constructive reduction to practice, and may 
temper criticisms of the latter.270 
 
Below, I outline motivations to explain why patentees might prefer 
working examples to prophetic examples; why inventors might be better off 
making the invention before filing a patent.  
 
Scientific Convention: In scientific disciplines, it is conventional to wait until 
experiments have actually been run before publishing the results. Scientific 
conventions often carry over to some extent into patents.271 Scientists control 
the timing of patent filing by deciding when to contact a lawyer to begin the 
patenting process. It may be that, because of the strong presumption in science 
that one does experiments before reporting results, scientists do not think to 
begin the process of filing a patent before obtaining actual data.  
 
Possibility of Error: While incorrect prophetic examples may not harm a patent 
application, a patent application filed on a concept that turns out not to work is 
a waste of time and money.272 Because filing a patent application can be 
                                                 
268 Mark A. Lemley, Ready for Patenting, 96 BU L. REV. 1171, 1178-79 (2016). 
(explaining that “[A]n inventor is better off filing a patent application as early as possible, 
before – or perhaps instead of – building a prototype or testing the invention.”); PATENT LAW, 
LEGAL AND ECONOMIC PRINCIPLES § 13:31 (2d ed. 2015) (“…because writing patent 
applications is often less expensive and time-consuming than doing actual research, the law 
creates an incentive to file patent applications before actual research involving them has been 
completed, and perhaps even begun. This constructive reduction to practice concept creates 
incentives to seek patents on purely theoretical designs and even guesses, rather than 
empirically tested, proven designs.”). 
269 Section II.A, supra. 
270 The doctrine is controversial and much debated. See, e.g., Christopher Cotropia, The 
Folly of Early Filing in Patent Law, 61 HASTINGS L.J. 65, 120 (2009) (recommending 
requiring actual reduction to practice); Jeanne C. Fromer, The Layers of Obviousness in Patent 
Law, 22 HARV. J.L. & TECH. 75, 101 (2008) (arguing that the doctrine should be questioned); 
Ouellette, supra note 10, at 1833 (calling the doctrine problematic); Seymore, supra note 10, at 
131 (listing constructive reduction to practice among the problems of the current enablement 
doctrine). 
271 E.g. FED. TRADE COMM’N, THE EVOLVING IP MARKETPLACE: ALIGNING PATENT 
NOTICE AND REMEDIES WITH COMPETITION, 84 (2011). See also, Janet Freilich & Jay Kesan, 
Towards Patent Standardization, 30 HARV. J. L. & TECH. 233, 242 (2017). 
272 E.g., INSTRUMENT SOCIETY OF AMERICA, ADVANCES IN INSTRUMENTATION: 
PROCEEDINGS OF THE INSTRUMENT SOCIETY OF AMERICA, Vol. 35, 380 (1980) (“speculation in 
 
expensive, inventors might prefer to conduct experiments to determine if the 
invention is operative before sinking money into a patent. Patents based on 
working examples should be more valuable than those based on prophetic 
examples because they describe tested inventions, not guesses.273  
 
Slight Enablement Advantage to Working Examples: The test for enablement 
is whether such a skilled artisan “could make or use the invention from the 
disclosures in the patent coupled with information known in the art without 
undue experimentation.”274 The meaning of the phrase “undue 
experimentation” has been subject to much debate, but the authoritative 
method for determining whether experimentation is “undue” is application of 
the Wands factors.275 Among the 8 Wands factors is “the existence of working 
examples.”276 The Wands factors do not mention prophetic examples. 
Although it is clear that prophetic examples can be used to enable a claim, their 
omission in the Wands factors may lead patent drafters to prefer, all else being 
equal, working examples. 
 
Use as Evidence by Opponents: Prophetic examples may paint a landscape of 
idealized methods for preparing a product and manners of using a product. 
Being prophetic, these methods and manners are not actually completed, nor 
are they always feasible. However, if the patent results in a product, and 
someone is injured by the product, the injured party may try to use the 
prophetic example as evidence in a products liability suit.277 Plaintiff-oriented 
products liability litigation guides recommend searching patents for proposed 
safety features, some of which will be prophetic, as evidence of what the 
defendant knew could be done.278 Defense-oriented litigation guides emphasize 
that lawyers should attempt to exclude prophetic examples or else offer 
“affirmative evidence about what was and was not done and tested.”279 
                                                                                                                                
contriving a ‘paper’ example often proves to be just that, unworkable except on paper.”). 
273 Russ Krajec, The First Patent: A Roadmap for a Startup’s Patent Portfolio, 
IPWATCHDOG (April 26, 2016), http://www.ipwatchdog.com/2016/04/26/first-patent-roadmap-
startups/id=68585/. 
274 United States v Telectronics, Inc., 857 F.2d 778, 785 (Fed. Cir. 1988). 
275 In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).  
276 Id. 
277 See, e.g., Condos v. Musculoskeletal Transplant Foundation, 208 F.Supp.2d 1226, 
1227 (2002). In Condos, the plaintiff argued that the defendant negligently failed to use 
cleaning methods described in two patents owned by the defendant, both of which contain only 
prophetic examples. Id. at 1231. The defendant explained that it is “currently attempting to 
implement those methods but has been unable to do so successfully.” Id. at 1228.  
278 See, e.g., ASSOCIATION OF TRIAL LAWYERS OF AMERICA, ATLA ANNUAL CONVENTION 
REFERENCE MATERIALS [Ann.2000 ATLA-CLE 2287] (2000) (“a patent search is warranted 
prior to filing [a products liability] suit.”). 
279 JOSEPH EVALL, WHAT EVERY PRODUCT LIABILITY LAWYER NEEDS TO KNOW ABOUT 
PATENTS AND THE COMPANY’S DEFENSE OF PATENT LITIGATION, 259 (2016), 
http://dri.org/docs/default-source/dri-online/course-materials/2010/drug-and-medical-
device/2010-drug-and-medical-device---14-what-every-product-liability-lawyer-needs-to-
know-about-patents-and-the-company-s-defense-of-patent-litigation.pdf?sfvrsn=4. 
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Cost in Attorney Time: It may be cheaper to write a prophetic example than to 
conduct some experiments, but it is not free. A major cost of filing a patent is 
the drafting attorney’s time. Each prophetic example adds to that time. Clients 
may be choosing to omit prophetic examples that are not absolutely essential.  
 
Changes in Patentees and Patenting Practices: The Patent Office first 
recognized prophetic examples in 1981. This was a period of change for patent 
law, with the passage of the Bayh-Dole Act in 1980280 and the creation of the 
Federal Circuit in 1982.281 The Bayh-Dole Act encouraged universities to file 
patents, and “turned universities into major players” in the patent system.282 
Since Bayh-Dole, the number of patents filed by universities has increased 
considerably. The USPTO reports that only 594 patents were filed by U.S. 
academic institutions in 1985, while 4,797 were filed in 2012.283 Universities 
are less likely to use prophetic examples – university-filed patents have a mean 
of 1.5 prophetic examples compared to 1.9 for non-university patents.284 This 
may be because university inventors must also publish papers in scientific 
journals, which require real results. 
 
Another possibility to explain the decrease in the number of prophetic 
examples over time is the corresponding increase in claim fees during this 
period. The USPTO has increased the fees for filing more than 20 claims 
several times. Increased claim fees reduce the number of claims filed by patent 
applicants.285 It may be that patentees cut out claims that covered more 
speculative material that was not core to their invention. These claims might be 
those typically enabled by prophetic examples, and thus the need for prophetic 
examples may have decreased. 
 
B.  Do Prophetic Examples Confuse Scientists? 
 
Section III asked whether prophetic examples are accurate and not 
misleading or whether prophetic examples are plagued by inaccuracy and are 
causes of confusion. I discuss these findings and their implications here. 
                                                 
280 Pub. L. No. 96-517, 94 Stat. 3015, 3019-28 (1980) (codified as amended at 35 U.S.C. 
200-212). 
281 Rochelle Cooper Dreyfuss, The Federal Circuit: A Case Study in Specialized Courts, 
64 N.Y.U. L. REV. 1, 1 (1989). 
282 Rebecca S. Eisenberg & Arti K. Rai, Bayh-Dole Reform and the Progress of 
Biomedicine, 66 LAW & CONTEMP. PROBS. 289, 290 (2003). 
283 United States Patent and Trademark Office, U.S. Colleges and Universities – Utility 
Patent Grants 1969-2012 (Sept. 1, 2017) available at 
https://www.uspto.gov/web/offices/ac/ido/oeip/taf/univ/doc/doc_info_2012.htm 
284 University patents were identified by looking for “university” or “college” in the name 
of the first assignee.  
285 E. Archontopoulos, et al., When Small is Beautiful: Measuring the Evolution and 
Consequences of the Voluminosity of Patent Applications at the EPO, 19 INFORMATION 
ECONOMICS & POLICY 103, 104 (2007). 
 
 
1. Prophetic Examples Are Often Inaccurate 
 
Implicit in the history and doctrine of prophetic examples is the assumption 
that prophetic examples are accurate.286 This Article does not directly assess 
the accuracy of prophetic examples, however, it produces several results that 
suggest that the assumption of accuracy is probably not correct.  
 
First, prophetic examples in unpredictable fields such as chemistry and 
biology are less likely to be correct than prophetic examples in predictable 
fields such as the mechanical sciences.287 This Article shows that unpredictable 
fields have a large number of prophetic examples – 536,271 examples in 
chemistry patents are prophetic and 416,436 examples in biology patents are 
prophetic. Prophetic examples in unpredictable fields are not inevitably 
incorrect. However, their prevalence in the unpredictable sciences suggests that 
we should not accept the assumption of accuracy and predictability of 
inventions constructively reduced to practice without further scrutiny.  
 
Second, the higher abandonment rate for patents with more prophetic 
examples is also consistent with prophetic examples being less accurate than 
working examples. Though there are many reasons why prophetic examples 
might be abandoned, one possibility is that the experiment was eventually tried 
and was found not to work.  
 
Third, detailed results are common in prophetic examples. It is unlikely – 
indeed, it would be surprising – if detailed examples with hypothetical 
numerical data were correct in the chemical and life sciences. That is simply 
not how those fields work.288 Irrespective of field, the more specific a 
prediction of experimental results, the less likely it is to be correct.  
 
Finally, prophetic examples are likely to be inaccurate because there is 
little incentive to be accurate. Though patentees would prefer not to be entirely 
incorrect, since that might result in a valueless patent, being merely somewhat 
wrong will often not be harmful.289 Moreover, there is some advantage to 
being vaguely incorrect. First, it does not give away all the cards to a 
competitor.290 Second, a vague prophetic example may enable a broader claim 
than a more specific prophetic example. 
 
                                                 
286 Section I.B.1, supra. 
287 Sean B. Seymore, Heightened Enablement in the Unpredictable Arts, 56 UCLA L. 
REV. 127, 144 (2009).  
288 Id. See also Jacob S. Sherkow, Patent Law’s Reproducibility Paradox, 66 DUKE L.J. 
845, 846 (2017). See also John P.A. Ioannidis, Why Most Published Research Findings Are 
False, 2 PLOS MED. 124, 124 (2005). 
289 And inoperative embodiments are not invalidating generally. MPEP § 2164.08(b). 
290 Note that being deliberately wrong or misleading is not permitted. See 37 C.F.R. § 
1.56. 
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The following example illustrates the advantages of vague and somewhat 
incorrect prophetic examples. Allergan Plc makes the widely-marketed product 
Latisse®, a prescription mascara that increases eyelash growth and 
thickness.291 One of the patents covering Latisse® is directed to use of 
prostaglandin F analogs to “arrest hair loss, reverse hair loss, and promote hair 
growth.”292 While much of the patent’s discussion relates to scalp hair loss, the 
patent includes the following prophetic example: 
 
A mascara composition is prepared. The composition comprises: 
[the example then lists 26 ingredients, including prostaglandin 
F]…A human female subject applies the composition each day. 
Specifically, for 6 weeks, the above composition is administered 
topically to the subject to darken and thicken eyelashes.293 
 
The prophetic example is partially right: there is a prostaglandin F analog that 
darkens and thickens eyelashes, and this became the commercially available 
Latisse® product. However, there are many details of the prophetic examples 
that do not reflect the final product. Most notably, the specific prostaglandin F 
analogs used in the prophetic example are not the same prostaglandin F 
analogs used in Latisse®. In addition, the concentration of the active ingredient 
is different in the prophetic example and the commercial product, as are the 
inactive ingredients and the period of administration. However, the differences 
between the prophetic example and Latisse® are inconsequential as a matter of 
patent law. The prophetic example enabled a broad claim to “a method of 
growing hair” using a broad range of thousands of different prostaglandin F 
analogs. The example was somewhat incorrect, but it was nonetheless useful 
for the patentee and to society, if society values eyelash thickeners.294 
 
The likely inaccuracy of prophetic examples is troubling. Prophetic 
examples are used to satisfy the enablement and written description 
requirements, but both of those requirements have an underlying assumption 
that prophetic examples are accurate.295 Since they are in many cases not 
accurate, it is illogical to allow patentees to use false prophecies to fulfill the 
disclosure requirements. This is a serious flaw in a fundamental aspect of the 
patent system. 
 
                                                 
291 LATISSE Highlights of Prescribing Information (2013), 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022369s007lbl.pdf. 
292 U.S. Patent No. 8,906,962, abstract (issued Dec. 9, 2014). 
293 Id. at Example 6. 
294 This issue is related to discussions about the failure of the enablement requirement to 
force full disclosure of all relevant details of the patented invention. See, e.g., Brian J. Love & 
Christopher B. Seaman, Best Mode Trade Secrets, 15 YALE J. L. & TECH. 1, 7-8 (2013); 
Nicholson Price Expired Patents, Trade Secrets, and Stymied Competition, NOTRE DAME L. 
REV. 4 (forthcoming 2018), available at https://ssrn.com/abstract=2888988. 
295 Section II.B, supra. 
 
2. Prophetic Examples Mislead Scientists 
 
Along with an assumption of accuracy, prophetic examples also rely on the 
assumption that they are not misleading.296 Above, I present direct evidence 
that prophetic examples are misleading – 99% of scientific papers cite 
prophetic examples as if the experiment had actually been conducted.297 This 
clearly demonstrates a deep misunderstanding of prophetic examples among 
scientists. And the problem is not restricted to the citing document. The citing 
document gets cited in turn by others, creating a chain where few readers 
would be aware that the underlying data is fictional. Additionally, patents are 
now frequently mined by databases that automatically extract information from 
patents.298 This is yet another way that untried experiments can infiltrate the 
general scientific literature.  
 
The findings presented in this Article impact the already-existing literature 
on problems with patent disclosure. This literature predominantly criticizes 
disclosures as difficult to read, insufficiently detailed, and not updated as 
research develops.299 Recent policy proposals have recommended either 
improving or updating patent disclosures or encouraging the development of 
ancillary information sources.300 However, some scholars criticize these 
proposals, arguing that disclosure is good enough,301 should not be a priority 
for the system,302 or that focus on the disclosure requirements detracts from 
                                                 
296 Id. 
297 Section III.D.2.b, supra. 
298 For example, the European Bioinformatics Institute has collected 15 million chemical 
structures using data-mining software that automatically extracts the structures from patents. 
Richard Van Noorden, Patent Database of 15 Million Chemical Structures Goes Public, 
NATURE NEWS BLOG (Dec. 11 2013), available at 
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and SciFinder (Jeremy R. Garritano, Evolution of SciFinder, 2011-2013: New Features, New 
Content, 32 SCI. & TECH. LIBRARIES 346, 355 (2013)). 
299 See, e.g., W. Nicholson Price II & Arti K. Rai, Manufacturing Barriers to Biologics 
Competition and Innovation, 101 IOWA L. REV. 1023, 1042-1048 (2016); Sean B. Seymore, 
The Teaching Function of Patents, 85 NOTRE DAME L. REV. 621, 627 (2010). 
300 Colleen Chien, Contextualizing Disclosure, 69 VAND. L. REV. 1849, 1869-72 (2016); 
Jeanne Fromer, Dynamic Patent Disclosure, 69 VAND. L. REV. 1715, 1722 (2016); Jason 
Rantanen, Peripheral Disclosure, 74 U. PITT. L. REV. 1, 18 (2012). 
301 E.g. J. Jonas Anderson, Secret Inventions, 23 BERKELEY TECH. L.J. 917, 940 (2011); 
Rantanen, supra note 300, at 16.  
302 Alan Devlin, The Misunderstood Function of Disclosure in Patent Law, 23 HARV. J.L. 
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incentives for patentees to create physical embodiments of their inventions.303  
 
 My data on prophetic examples strengthen broader criticisms of disclosure 
and lend urgency to calls for reform. Prophetic examples confuse scientists and 
spread misinformation. By doing so, prophetic examples function in a way that 
is antithetical to the disclosure function of patents. Prophetic experiments are a 
clear example of how patent disclosure is problematic. 
 
Prophetic examples are also consistent with a second line of disclosure 
scholarship. This literature focuses specifically on the criticism that 
conventions in patents are so different from writing conventions outside of 
patents that non-patent lawyers cannot understand patents.304 The conventions 
around prophetic examples are a world away from those dictating how 
scientific experiments are normally written, and this discrepancy is likely 
responsible for scientists’ confusion surrounding prophetic examples. Below, I 
outline some of these differences and how they create confusion. 
 
First, as they relate to prophetic examples, the rules of scientific writing are 
entirely opposite to the rules of patent writing. One scientist familiar with 
prophetic examples notes that writing a prophetic example in a scientific article 
would be “outright fraud”305 while another explains that a scientific paper 
“should not, in fact, have any prophetic component to it whatsoever. It better 
not. Unless its fraud.”306 One scientist reacted colorfully to learning about 
                                                                                                                                
& TECH. 401, 402 (2010). 
303 E.g. John Duffy, Reviving the Paper Patent Doctrine, 98 CORNELL. L. REV. 1359, 1361 
(2013) (arguing that the rise of “documentary disclosure theory” was used to justify the 
diminishment of doctrines preferencing actual reduction to practice). See also Christopher 
Cotropia, Physicalism and Patent Theory, 69 VAND. L. Rev. 1543, 1565 (2016). 
304 Kristen Osenga, Cooperative Patent Prosecution: Viewing Patents Through a 
Pragmatics Lens, 85 ST. JOHN’S L. REV. 115, 158 (2011). 
305 ROBERT M. RYDZEWSKI, REAL WORLD DRUG DISCOVERY: A CHEMIST’S GUIDE TO 
BIOTECH AND PHARMACEUTICAL RESEARCH 128 (2008). 
306 Wyeth v. Abbott Laboratories, 2009 WL 8478818 (D.N.J. Dec. 30, 2009) (Expert 
Testimony of Samuel Danishefsky, M.D.). (Document 103-18). See also Hoffmann-La Roche, 
Inc. v. Promega Corp., 323 F.3d 1354 (Fed. Cir. 2003) (Judge Newman, dissenting) 
(“[prophetic] examples have long been accepted in patent documents, unlike their prohibition 
in scientific articles.”). See also Coalition for Affordable Drugs X LLC v. Anacor 
Pharmaceuticals, IPR2015-01776, 20 (PTAB February 23, 2017) (explaining that a prior art 
reference containing prophetic examples “is a patent application that does not need to meet the 
standard of a peer-reviewed academic article.”). In another case, an expert testified “Expert: 
First of all, standards for reviewing manuscripts, and this is from my own work in both 
publishing scientific manuscripts and patent applications, are very different. In my experience 
to publish in a peer reviewed journal…it is crucial to have definitive evidence for a new 
chemical entity….I also understand that in patent applications the standards are different. 
There is an opportunity in patent applications, and I have done this with my own, to make 
prophetic statements. There is, as far as I am aware, no standard, no similar requirement to 
have to show everything that you describe as a prophetic example. Whereas, in scientific 
publications the idea of prophetic examples is discouraged, and in fact under most 
circumstances is not done. In order to get a peer reviewed article published one must have 
appropriate, adequate, rigorous experimental data.” Enzo Biochem, Inc. v. Applera Corp., 
 
prophetic examples, “[w]hat I call a fake experimental procedure is actually a 
prophetic example. What I call bullshit is a modus operandi.”307 The way that 
experiments are written is not only different in scientific articles as compared 
to patents; the practice of writing prophetic examples is actively offensive to 
many scientists. 
 
Prophetic examples not only deviate from scientific norms, they also 
deviate from the norms of everyday speech. In everyday conversation, the 
speaker is discouraged from making hypothetical statements unless these are 
expressed as opinions, hopes, or otherwise clearly marked as statements 
without evidentiary support.308 Prophetic examples do not follow these 
conventions. 
 
To the extent that prophetic examples confuse scientists, they are arguably 
unconstitutional. The Constitution authorizes patents to “promote the Progress 
of Science.”309 The Supreme Court has explained that “[i]nnovation, 
advancement, and things which add to the sum of useful knowledge are 
inherent requisites in a patent system” governed by that constitutional 
command.310 There has been little discussion of the meaning of “progress”311 
and courts have recently declined to find intellectual property provisions 
unconstitutional.312 However, there is at least a plausible argument that if 
prophetic examples mislead and hamper scientists they are regressing “the 
Progress of Science.” 
 
If it is important to have a patent system that provides information to 
scientists, it is vital that scientists properly understand the information so 
conveyed. To the extent that prophetic examples confuse readers, they are not 
compatible with the disclosure goal of the patent system. 
 
* * * 
 
Prophetic examples are justified on the grounds that they add value to 
patentees, which in turn incentivizes innovation that benefits society, that they 
are useful in certain special circumstances, and that they are likely to be 
accurate and not misleading. While prophetic examples likely add value to 
                                                                                                                                
2007 WL 6475274 (D. Conn. June 20, 2007) (Expert Testimony of David H. Sherman, Ph.D.) 
(Document 236-10). 
307 (emphasis in original). ORG PREP DAILY (June 29, 2007), 
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310 Graham v. John Deere Co., 383 U.S. 1, 6 (1966). 
311 Dotal Oliar, Making Sense of the Intellectual Property Clause: Promotion of Progress 
as a Limitation on Congress’s Intellectual Property Power, 94 Geo. L.J. 1771, 1844 (2006). 
312 E.g., Eldred v. Ashcroft, 537 U.S. 186, 188 (2003). Other cases are summarized in 
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individual patents, they appear to be present predominantly in lower value 
patents, which may have some cost to society. Further, mechanisms by which 
prophetic examples were predicted to add value – increasing breadth, early 
filing – are not apparent from the empirical evidence. In addition, even if 
prophetic examples are necessary in special circumstances, the vast majority of 
prophetic examples are not used in these special circumstances, and therefore 
cannot be justified on these grounds. Finally, there is evidence that prophetic 
examples are both inaccurate and misleading. In their present form, prophetic 
examples are a problem. 
 
C.  Reform: From Prophecies to Hypotheses 
 
Prophetic examples are a problem.  Justifications for prophetic examples 
are shaky, and their harms potentially extensive.  While prophetic examples 
and the consequences thereof might be helpful in some instances, and perhaps 
desirable if used in moderation, the traditional justifications become less 
tenable as the proportion of patents partially or completely relying on prophetic 
examples grows.   
 
Yet prophetic examples are deeply ingrained in the patent system and form 
an integral part of many patents.  So many patentees use prophetic examples 
that banning them would be a major shock to the system and potentially 
drastically change the way patents are written and the value of patents.  
Moreover, to be intellectually coherent, any ban on prophetic examples would 
need to be accompanied by an in-depth evaluation of the role of constructive 
reduction to practice in the patent system and how scope correlates with the 
disclosed invention.313  
 
Thus, banning prophetic examples entirely might therefore be too harmful 
to patentees and too drastic a change to the patent system – at least right now.  
Further, there are patentees who rely on prophetic examples for justifiable 
reasons – such as the inability to conduct a real experiment – and prophetic 
examples should not be removed without providing another mechanism to 
accommodate these patentees. In addition, there is nothing inherently wrong 
with making predictions about how a technology will progress in the future – 
in fact, such predictions could be valuable. I propose softer measures to 
mitigate the harms of prophetic examples with a less drastic shock to the patent 
system.  
 
1. Clearly Label Prophetic Examples 
 
To address the problems of prophetic examples without banning them, 
                                                 
313 Doctrines of constructive reduction to practice are currently criticized as “tentative and 
unsystematic” (Dmitry Karshtedt, The Completeness Requirement in Patent Law, 56 B.C. L. 
REV. 949, 991-92 (2015)) and the Patent Office’s guidelines “are no more helpful.” Ouellette, 
supra note Error! Bookmark not defined. at 7. 
 
certain aspects of prophetic examples should be reformed.  First, it should be 
easier for scientists and engineers reading patents to understand that, even 
though prophetic examples contain experimental data, it is not real data.  The 
present grammatical tense shift is insufficient for this purpose. It is 
unreasonable to expect non-lawyers to be aware of the meaning of the tense 
shift and even for lawyers who are aware the distinction is difficult to grasp.314   
 
The Patent Office currently requires patent applications to include certain 
section headings and to format some parts of the patent in standardized 
ways.315 The Patent Office should add a requirement that, for applications that 
include prophetic examples, the examples should all be grouped under a 
heading such as “Prophetic Examples.” However, only a heading is not 
sufficient because not all patent readers will understand the meaning of 
‘prophetic’.  Immediately underneath the heading, the PTO should require a 
disclaimer, perhaps in bold or italics, explaining the meaning of prophetic 
examples.  This may be a phrase such as “The examples below describe 
experiments that have not actually been conducted but that the patent applicant 
predicts will be functional.” The beginning and end of the prophetic examples 
section should be clearly delineated.  It may be desirable to mandate a separate 
heading for non-prophetic examples, perhaps “Working Examples” and an 
explanation there indicating that these examples have actually been conducted.  
These headings and explanations would make patents more user friendly and 
would prevent accidental interpretation of the data in prophetic examples are 
real data. 
 
Labeling would not only help scientists, it would also prevent translation 
errors. Many companies seek patent protection in more than one country.  
Generally, they will file an international patent application that will go through 
preliminary examination and then be examined in more detail in individual 
countries when the application enters the national stage. The international 
application is usually filed in the inventor’s native language and then, when it 
enters the national stage, is translated into the languages of countries where 
patent protection is sought. 
 
The translation process creates an opportunity for error.  Verb tense, which 
currently distinguishes between prophetic and working examples, may be 
mistranslated.   Some patent translating guides caution that “when translating 
the examples, it is important that the translation properly reflect the nature of 
the example (working or prophetic).”316 This is no simple exercise as “in some 
                                                 
314 Feldman, supra note 10 at 292 (explaining that use of the present tense is “unlikely to 
mean much to the uninitiated”). 
315 MPEP § 608. 
316 T. Dave Reed, International Patenting and the Translator: An Essential Partnership, 
THE ATA CHRONICLE 18 (June 2008), available at http://www.atanet.org/chronicle-online/wp-
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 Freilich 61 
languages there is no easy way to distinguish between the tenses.”317  
Disturbingly, most patent translation guides do not mention prophetic 
examples or tenses at all, suggesting that errors may arise from ignorance.  
Some firms caution, “one cannot assume that the foreign associates will 
translate the application correctly.”318  Moreover, there is greater potential for 
confusion in jurisdictions that do not accept prophetic examples.319  
 
The proposal to clearly label prophetic examples is the most feasible of the 
changes contemplated by this Article.  It is relatively simple and easy to 
implement, and the costs associated with compliance are minimal.  Attorneys 
are already mindful of what information in patents is prophetic, as they must 
consciously switch to writing in the present tense, so simply adding a 
standardized title and disclaimer should not require significant attorney or 
inventor effort.  Further, patent attorneys may favor the policy proposal 
because heightened separation of prophetic and working examples during the 
prosecution process may prevent accidental inclusion of prophetic information 
in the past tense, which is inequitable conduct. 
 
Additionally, it would be helpful to ban results in prophetic examples. 
Results are probably the most misleading part of prophetic examples and the 
greatest deviation from scientific norms. Not all prophetic examples include 
results, but clearly many do. Removing results from prophetic examples would 
prevent some of the confusion surrounding prophetic examples. 
 
Further, banning results would have a minimal effect on patentees.  Patent 
applicants often need to include examples for enablement or written 
description purposes, but nothing in patent doctrine requires these examples to 
have results or interprets the example as more valuable to patent validity if it 
has a result.  There are some doctrines, such as utility, where the ultimate use 
of the invention would still have to be stated in the patent, but there is no 
reason that would have to be done in the context of a prophetic example.  Thus, 
banning results in prophetic examples would benefit the reader with little harm 
to the patentee. 
 
2. Give Patentees a Grace Period to Update Prophetic Examples 
 
In some cases, patent applicants fully intend to conduct the experiments 
recounted in prophetic examples.  These applicants file prophetic examples 
because they are not able to conduct the experiments before the application 
needs to be filed.  This can occur for many reasons such as temporary lapses in 
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318Fish & Tsang Intellectual Property Law, Chapter 10 – PCT and Foreign Patent 
Practice & Procedure,  http://www.fishiplaw.com/chapter-10-pct-and-foreign-patent-practice-
a-procedure. 
319 Id. (“In Japan, for example, practitioners are not generally used to prophetic examples 
[because they are not permitted] and may well translate a prophetic example in the past tense.” 
 
funding, needing the patent before funding can be obtained, or long approval 
processes for human trials.  These may be legitimate uses for prophetic 
examples.   
 
If patentees plan to conduct the described experiments, they should be 
allowed to file a patent with prophetic examples as a placeholder with the 
requirement that they update the patent within a period of time with the results 
of the experiment.  Experiments that do not work should be left in, but updated 
with an explanation that they did not work.  This would help combat 
underreporting of negative results, a major problem in the research world.320 
 
A key advantage of this policy suggestion is that it would retain some of 
the benefits for patent applicants in situations where prophetic examples are 
necessary.  Take, for instance, a start-up who cannot raise enough money to 
conduct an experiment without venture capital funding, but cannot obtain 
venture capital funding without filing a patent.  The start-up could file a patent 
with a prophetic example, seek funding, and then update the example several 
years later.  
 
As present, it is not possible to update prophetic examples.  Examples in 
patents cannot be changed (other than for clerical errors) after the patent is 
granted.321 It is also difficult to update examples during examination and 
adding updated data would likely require the applicant to file a new application 
based on the original application and therefore lose the original filing date.322  
These rules should be loosened to allow patentees and applicants to update 
prophetic examples. Even if requiring or encouraging updating is not desirable, 
patentees and applicants should at least have the opportunity to update if they 
so choose.  Although this would be a major change for the US patent system, 
other countries allow inventors to update their applications under certain 
circumstances, suggesting that such a proposal might be workable.323 
 
3. Remove Presumption of Enablement 
 
If patentees had a grace period to update prophetic examples, examples that 
were not updated at the end of the period should be presumptively non-
enabled.  An example is enabled if a person of ordinary skill in the art could 
                                                 
320 E.g., Paul Hsieh, The Positive Value of Negative Drug Trials, FORBES (August 30, 
2015), available at http://www.forbes.com/sites/paulhsieh/2015/08/30/the-positive-value-of-
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321 35 U.S.C. § 255. 
322MPEP 201.08. 
323 For example, Australia allows inventors to add working examples to the specification 
as long as these examples do not encompass matter that was “not in substance disclosed” in the 
specification as filed.   Shann Kerner, Andrej Barbic, & Kyle Robertson, Examples 
Requirement for Patentability of Inventions in US and Foreign Jurisdictions, 3 Bloomberg 
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make and use the invention based on the disclosed information.324 This means 
that the example must both disclose a functional invention and disclose it in 
sufficient detail that it could be replicated without undue experimentation. At 
present, examples in granted patents are presumptively enabled,325 meaning 
that a challenger alleging that the patent was invalid would have to prove that 
the prophetic example was not enabled. If prophetic examples were 
presumptively non-enabled, the burden would shift and the patentee would 
have to prove that the prophetic example was enabled.  If such a policy were 
implemented, the patentee should be able to update the example at any point 
and shift to presumptive enablement.  However, this should be coupled with a 
prior user defense to infringement lasting from the expiration of the grace 
period to publication of the updated results in order to avoid “submarine 
examples.”326 
 
This would not only have an effect in litigation, it would also have an 
effect on downstream research in the area.  If a prior patent has disclosed an 
invention, a later patent cannot claim it, because the invention is novel.327  
However, earlier disclosure is only a bar to novelty if the earlier invention is 
enabled. Since granted patents are presumptively enabled, it is risky to seek a 
patent on an invention disclosed in a granted patent – even if the invention is 
likely not enabled – because the later patentee must show non-enablement.  
Thus, fewer inventors will conduct research in that area.  If non-updated 
prophetic examples were presumptively non-enabled, it might reduce the 
chilling effect and encourage others to conduct experiments in these areas. 
 
4. Evaluate Prophetic Examples Based on Underlying Evidence 
 
When evaluating a patent for enablement, examiners should not simply 
accept prophetic examples.  Instead, examiners should review the example 
with an eye towards determining if it would really work.  Patent applicants 
should include an explanation of why they believe the prophetic example 
would work, including any calculations or reasoning necessary to understand 
the prediction. A patent examiner could then give greater weight to well-
reasoned prophetic examples in areas where the science is predictable, and less 
weight to wild predictions. Greater explanation of the reasoning behind 
prophetic examples would both help examiners and help patent readers 
determine if the prediction is useful. 
 
*              *              * 
 
                                                 
324 35 USC § 112. 
325 See 35 U.S.C § 282 (“A patent shall be presumed valid.”). 
326 I use this term by analogy to “submarine patents” where patentees “delay the issuance 
of their patent precisely in order to surprise a mature industry.” Mark A. Lemley & Kimberly 
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I recognize that these policy suggestions would not completely remedy all 
ills associated with prophetic examples. Prophetic examples should be studied 
further – particularly in conjunction with the larger question of constructive 
reduction to research more generally – in order to determine if greater reform 
is necessary. 
 
CONCLUSION 
 
At least 17% of experiments in patents from the studied industries – 
chemistry and biology – include made up data. The practice arose out of early 
twentieth-century notions of fairness across industries as well as out of 
administrative necessity. In an era where patent scholars, the FDA, and 
scientists more broadly are grappling with an irreproducibility “crisis,”328 it is 
time to re-think the justifications for prophetic examples. This Article presents 
evidence that questions the traditional foundations for the practice of including 
prophecy in patents. It further finds that patent readers, particularly scientists, 
are enormously confused about prophetic examples and that such examples 
lead to a plague of mis-citations and the infiltration of made up data into 
reputable scientific publications. Prophetic examples are undoubtedly useful 
for some patentees, but they also have clear harms. These competing effects, 
combined with the ubiquity of made up data in chemistry and biology patents 
means that patent scholars, practitioners, and policy makers must be more 
aware of prophetic examples. 
 
* * *
                                                 
328 See Sherkow, supra note 288. See also Monya Baker, Is There a Reproducibility 
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APPENDIX 1: SUMMARY STATISTICS – CHEMISTRY & BIOLOGY GRANTED PATENTS 
Patents are divided into ten groups based on the number of prophetic examples in the patent 
  
Group 
(Patents) 
0 1 2 3 4 5 6 7 8 9 
Number of prophetic 
examples 
0 1 2 3 4 5 6-8 9-11 12-17 18-754 
Number of patents 391,839 53,216 25,520 17,709 12,651 9,679 13,326 11,881 10,829 12,756 
Mean priority year 1995 1994 1993 1992 1991 1991 1990 1990 1988 1988 
Mean number of non-
prophetic (working) 
examples 
9 9 8 9 8 7 7 8 8 15 
% of patents that are 
continuations 
16 19 20 18 17 16 15 15 13 14 
% of patents that have 
foreign priority 
40 30 31 35 37 38 40 43 43 39 
Mean length of 
specification (number of 
words) 
10,168 11,123 11,376 11,118 10,874 10,868 11,560 12,620 14,535 23,551 
Mean number of 
backwards citations 
17 20 21 19 19 18 20 19 16 19 
% of patents filed by small 
entities 
17 21 21 20 18 17 15 14 12 9 
% of patents paying year 4 
maintenance fee 
82 82 81 80 80 80 81 79 79 77 
% of patents that have 
been litigated 
0.6 0.8 0.8 0.7 0.7 0.5 0.7 0.4 0.6 0.5 
Mean average number of 
words in independent 
claims 
128 128 126 126 126 132 136 142 152 184 
Mean number of claims 14 15 15 15 15 15 15 15 15 16 
 
APPENDIX 2: SUMMARY STATISTICS – CHEMISTRY & BIOLOGY APPLICATIONS 
Applications are divided into ten groups based on the number of prophetic examples in the Applications 
 
 
Group 
(Patents) 
0 1 2 3 4 5 6 7 8 9 
Number of prophetic 
examples 
0 1 2 3 4 5 6 7-10 11-15 16-754 
Number of applications 271,820 68,250 33,577 20,893 14,585 10,292 7,939 13,965 10,115 12,307 
Mean priority year 2007 2008 2007 2007 2007 2007 2007 2007 2007 2007 
Mean number of non-
prophetic (working) 
examples 
10 10 11 13 13 13 13 14 18 33 
% of applications that are 
continuations 
25 27 29 28 28 29 31 29 29 36 
Mean length of 
specification (number of 
words) 
15,923 17,954 19,192 20,024 21,006 21,377 24,821 25,579 29,734 53,767 
Mean number of claims 23 24 24 25 24 24 24 24 24 28 
% of applications that are 
granted 
44 43 43 44 44 44 43 45 45 48 
APPENDIX 3: REGRESSIONS - CHEMISTRY & BIOLOGY GRANTED PATENTS 
Correlation Between Number of Prophetic Examples and Value Measures 
 
  
                                                 
329 Only patents issued before 2013 are included in the regression, because patents issued later will not have had 
the opportunity to pay the maintenance fee. 
330 Only patents issued before 2015 are included in the regression, because forward citation data was collected 
from a PTO file last updated in 2014. This measure only includes forward citations by US patents, not by applications, 
foreign patents, or non-patent literature.  
 
 
Variable 
(1) 
Payment of First 
Maintenance Fee 
(logit regression; 
odds ratios)329 
(2) 
Forward Citations 
(poisson 
regression; 
incident rate 
ratios)330 
(3) 
Litigated 
(logit 
regression;  
odds ratios) 
(4) 
Orange Book 
Listed (logit 
regression;  
odds ratios) 
0 prophetic examples 
 
1 prophetic example 
 
2 prophetic examples 
 
3 prophetic examples 
 
4 prophetic examples 
 
5 prophetic examples 
 
6-8 prophetic examples 
 
9-11 prophetic examples 
 
12-17 prophetic examples 
 
18-754 prophetic examples 
 
Year since issuance offset 
 
Priority year  
 
Foreign-filed  
 
Small entity 
 
Orange book listed 
 
Industry effect 
 
N= 
Reference 
 
0.91*** 
 
0.85*** 
 
0.83*** 
 
0.81*** 
 
0.79*** 
 
0.80*** 
 
0.75*** 
 
0.69*** 
 
0.66*** 
 
 
 
0.99*** 
 
0.71*** 
 
1.03*** 
 
 
 
Yes 
 
455,094 
Reference 
 
1.05*** 
 
1.02*** 
 
0.97*** 
 
0.97*** 
 
1.02*** 
 
0.97*** 
 
0.95*** 
 
0.95*** 
 
0.92*** 
 
Yes 
 
1.01*** 
 
0.66*** 
 
1.13*** 
 
 
 
Yes 
 
497,653 
Reference 
 
1.06 
 
1.15 
 
0.92 
 
1.06 
 
0.90 
 
0.96 
 
0.48*** 
 
0.94 
 
0.64** 
 
Yes 
 
0.88*** 
 
0.41*** 
 
1.18*** 
 
71.64*** 
 
Yes 
 
559,406 
Reference 
 
1.17 
 
1.55*** 
 
1.35* 
 
1.21 
 
0.99 
 
1.67*** 
 
1.90*** 
 
1.70** 
 
1.28 
 
 
 
1.02* 
 
0.89 
 
0.41*** 
 
 
 
Yes 
 
559,406 
 
 
Correlation Between Number of Prophetic Examples and Entity Size 
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Variable 
(5) 
Small Entity 
(logit regression; 
odds ratios)331 
0 prophetic examples 
 
1 prophetic example 
 
2 prophetic examples 
 
3 prophetic examples 
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APPENDIX 4: REGRESSIONS - CHEMISTRY & BIOLOGY APPLICATIONS 
 
Figure 4: Correlation Between Number of Prophetic Examples and Grant Rate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
332 Only patents issued before 2011 are included, since applications may take several years to be granted. 
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APPENDIX 5: EFFECT OF ENTITY SIZE TRENDS ON NUMBER OF PROPHETIC EXAMPLES IN PHARMACEUTICAL PATENTS 
 
The number of prophetic examples has been decreasing over time. For pharmaceutical patents (defined using NBER’s industry 
classification), this may be due to an increase in patenting by small companies. Clockwise from top left: 5(a) shows the decrease in 
prophetic examples per patent over all pharmaceutical patents (N=233,823). 5(b) shows the increasing percent of pharmaceutical patents 
filed by small entities (N=142,481); 5(c) shows that the use of number of prophetic examples per patent filed by small entities has stayed 
relatively steady over time (N=41,681). 5(d) shows the same, but for large entities (N=110,800). 
